Document:

Letter Agreement

 EXECUTION COPY 
 EXHIBIT 10.37 
 THOMAS HIGH PERFORMANCE GREEN FUND, L.P. 
 C/O THOMAS PROPERTIES GROUP, L.P. 
 CITY
NATIONAL PLAZA 
 515 SOUTH FLOWER STREET 
 SIXTH FLOOR 
 LOS ANGELES, CA 90071 
 December 18, 2007 
 California State Teachers’ Retirement System 
 7667 Folsom Boulevard, Suite 250 
 Sacramento, California 95826 
 Attention: [ ... ]* 
 Re: Thomas High Performance Green Fund, L.P. 
 Ladies and Gentlemen: 
 Reference is made to the above limited partnership
(the “Partnership”). Terms used herein without definition have the meanings ascribed to them in the Limited Partnership Agreement of the Partnership, of even date herewith (the “Agreement”). 
 1. [ ....]* 
 2. Capital Calls.
The General Partner shall not, for so long as any Subscription Line Indebtedness is in effect issue a Capital Call requiring a Capital Contribution from the Investor to be made to any account other than the collateral account identified in the
Investor Consent Letter executed by the Investor in favor of the Subscription Line Lender in connection with the Subscription Line Indebtedness. 
 3. Opinion of Counsel. The General Partner agrees that, for purposes of any provision of the Agreement, the Subscription Agreement and any other agreement requiring the delivery of an opinion of counsel by Investor, the staff counsel
of the Investor will constitute counsel acceptable to the General Partner. 
 4. Immunity. The General Partner acknowledges that
Investor reserves all immunities, defenses, rights or actions arising out of its sovereign status or under the Eleventh Amendment to the United States Constitution, and no waiver of any such immunities, defenses, rights or actions shall be implied
or otherwise deemed to exist by reason of its entry into the Agreement or any other agreement related thereto, by any express or implied provision thereof or by any actions or omissions to act by Investor or any representative or agent of Investor,
whether taken pursuant to the Agreement or prior to Investor’s execution thereof. 
  
  
 * Confidential Information (indicated by [...]) has
been omitted and filed separately with the Securities and Exchange Commission. 

 5. Blind Pool Investments. The General Partner agrees that the Partnership shall not invest in
blind pool investment funds without the prior approval of the Advisory Committee and in the event such approval is granted, no Management Fee shall be paid in connection with such Investment. 
 6. No Personal Indemnification Obligation. The General Partner hereby confirms that the Agreement and the Subscription Agreement do not impose any
personal indemnification obligations on the Investor for acts of other Persons and shall not be applied or construed to require the Investor to provide indemnification directly to any person or entity thereunder. The Investor, however, acknowledges
that it is obligated as a Limited Partner to make Capital Contributions (to the extent of its unfunded Capital Commitment) as called pursuant to the terms of the Agreement (including, without limitation, for purposes of funding any indemnification
obligation of the Partnership pursuant to Section 9.1 of the Agreement), and that nothing herein shall relieve the Investor from its responsibility for the truth and accuracy of its representation, warranties and covenants in the Subscription
Agreement. 
 7. Unfunded Capital Commitment. The Investor shall have no obligation or liability to contribute capital to the
Partnership in excess of its unfunded Capital Commitment. Except to the extent provided under the Delaware Revised Uniform Limited Partnership Act, the Investor shall have no obligation to return any distributions it has received nor shall Investor
be personally liable to any third party for any liability or other obligation of the Partnership. Nothing in the preceding sentence shall limit the Investor’s liability to the Partnership in connection with a default by the Investor under the
Agreement or its Subscription Agreement. 
 8. Subscription Line Indebtedness. In the event that the Partnership makes any borrowings
under any Subscription Line Indebtedness arrangement and such borrowings are not repaid within ninety (90) days of being drawn, the Investor’s Management Fee payment due for the calendar quarters in which such repayment has not been made
shall be reduced by an amount equal to the annual rate of 0.50% of such unrepaid borrowing balance for the number of days during each such calendar quarter in which such balance remained unpaid for more than such 90-day period. 
 9. Distributions. Notwithstanding anything to the contrary in Section 5.1(b) of the Agreement, the General Partner hereby confirms that the
Net Distributable Cash allocated to the Investor pursuant to Section 5.1(b) of the Agreement shall be distributed in the following manner: 
 (a) [ ... ]* 
 (b) [ ... ]*; 
 (c) [ ... ]*; and 
 (d) [ ... ]* 
  
  
 * Confidential Information (indicated by [...]) has been omitted and filed separately with the Securities and Exchange Commission. 
  

 2 

 10. Allocations. Notwithstanding anything to the contrary in Section 4.2 of the Agreement
other than the application of Section 4.3, the General Partner hereby confirms that the Profits with respect to an Investment attributed to the Investor’s Percentage Interest shall be allocated in the following manner: 
 (a) [ ... ]* 
 (b) [ ... ]*; 
 (c) [ ... ]*; and 
 (d) [ ... ]* 
 11.
Over-Distributions. Notwithstanding anything to the contrary in Section 14.2 of the Agreement, the Partnership and the General Partner hereby agree that with respect to the Investor, upon the Partnership’s sale or other disposition
of its entire interest in any Investment (including, without limitation, written-off Investments), the General Partner shall determine whether the Carried Interest Distributions otherwise previously paid to the General Partner or payable to the
General Partner from the Net Distributable Cash from such Investment and all prior Investments allocable to the Investor, shall be redistributed as among the General Partner and the Investor (or returned by the General Partner and redistributed, if
necessary) in accordance with the following: 
 (a) After giving effect to any Carried Interest Distributions that would
otherwise be made to the General Partner from Net Distributable Cash allocable to the Investor pursuant to paragraph 9 on account of such sale or other distribution, as well as all other Carried Interest Distributions previously distributed to the
General Partner from Net Distributable Cash allocable to the Investor, the General Partner shall calculate the amount of any Over-Distribution that would exist if, as of the date of such sale or other disposition, the Partnership were finally
liquidated, all of the Partnership’s remaining Investments were sold to a third party for an all cash price equal to their most recent values established in accordance with the most recent valuation of such Investments conducted pursuant to the
Valuation Plan approved by the Advisory Committee pursuant to Section 6.6(e) of the Agreement (or if an Investment has been acquired by the Partnership but has not yet been valued under such Valuation Plan, the Partnership’s initial
acquisition cost of such Investment) and from the proceeds of such deemed sale(s): (i) normal selling costs (including without limitation brokerage commissions, title, recording and escrow fees, and transfer taxes, to the extent applicable)
customarily paid by a seller were paid; (ii) the remaining liabilities of the Partnership to creditors other than Partners or their Affiliates were liquidated pursuant to Section 14.1(b); (iii) reserves in an amount reasonably
determined by the General Partner were established for any contingent, conditional or unmatured liabilities or obligations of the Partnership pursuant to Section 14.4(b); and (iv) the Partnership distributed any remaining amounts to the
Partners in accordance with the provisions of paragraph 9 above. When implementing this paragraph 11 with respect to any Investment owned through a Vehicle 
  
  
 * Confidential Information (indicated by [...]) has
been omitted and filed separately with the Securities and Exchange Commission. 
  

 3 

 
and determining the proceeds which would be received by the Partnership upon a sale thereof, the provisions of the applicable Vehicle, including without
limitation the provisions governing the rights to distributions as between the Partnership and the other Vehicle members, as well as all liabilities and reserves of the applicable Vehicle, shall be taken into account. 
 (b) The Partnership’s independent public accountants shall audit the General Partner’s calculations in accordance with paragraph
11(a) and report the results of such audit to the Investor for review and approval. If required as a result of such audit, any necessary revisions in the General Partner’s calculations in accordance with paragraph 11(a) shall be made.

 (c) Within fifteen (15) days after the completion of the audit and approval process pursuant to paragraph 11(b),
(i) if it is determined pursuant to paragraph 11(a) and (b) that no Over-Distribution exists, the General Partner shall distribute the Net Distributable Cash from such Investment allocable to the Investor to the General Partner and the
Investor in accordance with paragraph 9 above, and (ii) if it is determined pursuant to paragraph 11(a) and (b) that an Over-Distribution exists, the General Partner shall reduce the amount of Net Distributable Cash allocable to the
Investor from such Investment that would otherwise be payable to the General Partner and, if need be, contribute to the Partnership for distribution to the Investor, an aggregate amount equal to the lesser of (i) the amount of any
Over-Distribution that is determined to exist pursuant to paragraph 11(a) and (b); and (ii) the aggregate of all Carried Interest Distributions previously distributed or then otherwise distributable to the General Partner. 
 (d) Any amount that the General Partner is obligated to distribute to the Investor pursuant to paragraph 11(c) and which is not so
distributed within fifteen (15) days after the completion of the audit and approval process pursuant to paragraph 11(b) (the “Claw Back Amount”) shall be treated as a loan to the General Partner from the Investor (a
“Claw Back Loan”). Each Claw Back Loan shall bear interest at the rate of eighteen percent (18%) per annum, compounded monthly, from the date of the completion of the audit and approval process pursuant to paragraph 11(b). In
such event, all amounts that would otherwise have been distributed or paid by the Partnership to the General Partner or any Affiliate of the General Partner (including without limitation amounts distributable or payable upon the dissolution of the
Partnership) (“Claw Back Loan Payments”) will, for all purposes of the Agreement, be deemed and accounted for as if distributed or paid to the General Partner or Affiliate, but will in fact be paid directly to the Investor by the
Partnership on account of such Claw Back Loan, with Claw Back Loan Payments being first applied to interest accrued on such Claw Back Loan and then to reduce the principal amount of such Claw Back Loan. In the event there is more than one
(1) outstanding Claw Back Loan, then each such Claw Back Loan Payment shall be applied thereto in proportion to the amounts outstanding under all such Claw Back Loans. The General Partner shall execute, acknowledge, deliver, file and/or record,
as appropriate, any documents, instruments and agreements reasonably necessary to direct such Claw Back Loan Payments to the Investor. If not sooner repaid, all principal and interest on Claw Back Loans shall become immediately due and payable

  

 4 

 
upon the sale, transfer or other disposition of all or substantially all of the assets of the Partnership or any other dissolution of the Partnership.

 (e) TPG and TPG, L.P. (collectively, the “Guarantor”) irrevocably guaranty the full and prompt payment or
performance when due of the General Partner’s obligations under this paragraph 11. If the General Partner fails to satisfy an obligation under this paragraph 11 after such obligation has become fixed and due, the Investor may give written
notice thereof to the Guarantor and the Guarantor shall cause such obligation to be satisfied within ten (10) days after receiving such notice. 
 12. Management Fees. [ ... ]* 
 13. Acquisition Fee. In addition to the Management
Fee payable with respect to the Investor’s Invested Capital pursuant to paragraph 12 above, the Investor shall make Capital Contributions from its Capital Commitments so that the Partnership can pay a one-time fee to the General Partner with
respect to each Investment, at the time of acquisition of such Investment by the Partnership, equal to the lesser of (a) [ ... ]*. The acquisition fee payable to the General Partner with respect to Investments which are development projects
shall be payable at the time the applicable construction contract is fully executed. Such acquisition fee shall not apply to projects which are transferred from TPG or its Affiliates to the Partnership. 
 14. Voting. With respect to all matters submitted to a vote, consent or approval of the Limited Partners, upon the Investor’s written
request, the General Partner shall deliver to Investor a written report indicating the identity of those Limited Partners voting in favor of, consenting to or otherwise approving such matter and those Limited Partners voting against, refusing to
consent to or otherwise disapproving any such matter. 
 15. ERISA. The General Partner confirms that if 33% or more of the aggregate
Capital Commitments are removed or excused from any particular proposed Investment in accordance with Section 6.2 of the Agreement, the General Partner shall not make such Investment without the approval of the Investor. 
 16. Advisory Committee. The General Partner confirms that the Investor shall have the right to be appointed to the Advisory Committee (subject to
the suspension for default provisions of Section 6.6 of the Agreement) and to appoint a representative to attend meetings of the Advisory Committee on its behalf. The General Partner confirms that in connection with any in-person meeting of the
Advisory Committee, the Partnership shall arrange for and pay the cost of the transportation and hotel room for the Investor’s designated representative on the Advisory Committee to attend the meeting in accordance with Section 6.6(a) of
the Agreement. 
 17. Representations and Warranties of the General Partner. The General Partner on behalf of itself and the
Partnership represents and warrants to and agrees with the Investor that each of the following statements will be true on the date hereof and on the closing of the Investor’s Interest: 
  
  
 * Confidential Information (indicated by [...]) has been omitted and filed separately with the Securities and Exchange Commission. 
  

 5 

 (a) The General Partner is a Delaware limited partnership duly formed and validly
existing in good standing under the laws of Delaware with all requisite power and authority to enter into each Subscription Agreement and the Agreement, to carry out the provisions and conditions hereof and thereof, and to consummate the
transactions contemplated hereby and thereby. 
 (b) The Partnership is a limited partnership duly formed and validly existing
in good standing under the laws of Delaware with all requisite partnership power and authority to own the properties it proposes to acquire and to conduct its business as described in the Agreement and to consummate the transactions contemplated
hereby and under the Agreement. 
 (c) The execution, delivery and performance by the General Partner of the Agreement and
this letter agreement have been authorized by all necessary action on behalf of the General Partner, and the Agreement and this letter agreement are legal, valid and binding agreements of the General Partner and the Partnership, enforceable against
the General Partner and the Partnership in accordance with their terms, subject to applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and similar laws affecting creditors’ rights and remedies generally and
subject, as to enforceability to general principles of equity, including principles of commercial reasonableness, good faith and fair dealing (regardless of whether enforcement is sought in a proceeding at law or in equity). 
 (d) The execution and delivery of the Agreement and this letter agreement, the consummation of the transactions contemplated thereby and
the performance of the Partnership’s and the General Partner’s respective obligations under the Agreement and this letter agreement will not (i) conflict with or result in any violation of or default under any provision of the
Agreement or any other agreement or instrument to which any of the Partnership or the General Partner is a party or by which any of them or any of their respective properties are bound, or any license, permit, franchise or regulation applicable to
the Partnership or the General Partner or their respective businesses or properties, (ii) violate any statute, regulation, law, order, writ, injunction, judgment or decree to which the Partnership or the General Partner or any of their
respective properties is subject which would materially and adversely affect the operations, properties or business of the Partnership or the obligations of the General Partner under the Agreement or (iii) require the consent, approval or
authorization of, or filing, registration or qualification with, any court or governmental authority on the part of the Partnership or the General Partner, except with respect to those consents, approvals, authorizations and filings customarily
required in the course of issuing limited partnership interests in private placement transactions or acquiring, financing, managing and disposing of real properties. 
 (e) Upon execution and delivery to the General Partner of this letter agreement and the Subscription Agreement by the Investor and
acceptance thereof by the General Partner, the Investor will have been duly admitted as a Limited Partner (as defined in the Agreement) of the Partnership, entitled to all the benefits, and subject to all 

  

 6 

 
the obligations, of a Limited Partner under the Agreement and the Delaware Revised Uniform Limited Partnership Act, as amended from time to time. 

(f) The offer and sale of an Interest to the Investor as contemplated by the Agreement do not require registration under the United
States Securities Act of 1933, as amended (assuming the accuracy of the representations and warranties of other Limited Partners contained in the other Subscription Agreements.) 
 (g) The Partnership is not required to register as an “investment company” under the Investment Company Act (assuming the
accuracy of the representations and warranties of the other Limited Partners contained in the other Subscription Agreements). 
 (h) To the best of the General Partner’s knowledge, the Partnership and the General Partner are in full compliance and will remain in full compliance with all federal laws and regulations related to investments, directly or through
either a domestic or foreign subsidiary, in countries outside of the United States of America, related to laws and regulations which seek to prohibit or limit business activities which pose the potential for supporting or advancing terrorist related
activities, particularly business activities in sanctioned or sensitive foreign countries (as identified by the U.S. federal government, the Department of Treasury, or the Securities and Exchange Commission). 
 (i) The Private Placement Memorandum and all supplements thereto (including the Agreement) provided to the Investor do not contain any
untrue statements of a material fact or any omission of a material fact that would make the statements contained therein misleading. 
 18.
Review of Reports. The General Partner agrees to work with the Investor and its authorized consultants to provide on a periodic basis, upon written request of the Investor, additional reports, including data regarding the income of the
Partnership, the valuation of Investments, and total returns, including time-weighted returns, of the Investor’s investment in the Partnership in a presentation reasonably satisfactory to the Investor. The General Partner further agrees that,
at the reasonable request of the Investor, it will review the Partnership performance and the valuation of Investments with the Investor and its consultants. 
 19. The PrivateEdge Group. The Investor has contracted with State Street’s The PrivateEdge Group (TPEG) to report on the performance and diversification characteristics of each real estate investment in
their portfolio. TPEG provides private equity and real estate clients with performance measurement, accounting and portfolio management reporting and analysis, and consulting services. On a quarterly basis, the General Partner shall submit financial
and characteristic information, in the manner reasonably requested by TPEG, which will allow TPEG to calculate returns and portfolio diversification analysis as agreed to with the Investor. 
 20. Liabilities after Termination. The General Partner confirms that after the expiration of the Term of the Partnership, the Investor shall have
no liabilities to the Partnership under the Partnership Agreement, including liability to make Capital Contributions, other than as required by applicable law. 
  

 7 

 21. Tax Withholding. The General Partner acknowledges that the Investor, as a tax-exempt entity
under U.S. federal, state and local laws, has never been subject to, and is unlikely to be subject to, any tax withholding requirements of U.S. federal, state or local laws. Before withholding and paying over to any tax authority any amount
purportedly representing a tax liability of the Investor pursuant to the Agreement, the General Partner will provide the Investor written notice of the claim of any U.S. or non-U.S. tax authority that such withholding and payment is required by law
and provide the Investor the opportunity to contest such claim during any period such contest does not subject the Partnership or the General Partner to any potential liability to such taxing authority of any such claimed withholding and payment.

 22. Transfer of Interest. The General Partner will not withhold its consent to the Transfer by the Investor to any (i) person
or entity which is a successor to the Investor under state law of all (but not less than all) of the Investor’s Interest or (ii) a wholly owned entity, and in each case, the transferee shall be admitted to the Partnership as a substituted
Limited Partner upon the execution of documentation reflecting such admittance. 
 23. Records. The General Partner hereby agrees to
preserve all financial and accounting records pertaining to the Agreement during the term of the Partnership and for four years thereafter, and during such period, Investor or its designated consultant, upon reasonable notice, shall have the right
to audit such records in regard thereto to the fullest extent permitted by law. The General Partner shall have the right to preserve all records and accounts in original form or on microfilm, magnetic tape, or any similar process. 
 24. Financial Information. In consideration of the Investor’s status as an instrumentality of the State of California, the General Partner
agrees that for purposes of the Agreement and the other agreements executed in connection therewith, to the extent the Investor is required to provide the General Partner, the Partnership or any Subscription Line Indebtedness lender with financial
information regarding the Investor, such information shall be limited to such financial information regarding the Investor that is publicly available. 
 25. Subscription Line Indebtedness. The General Partner confirms that to the extent requested by the Subscription Line Lender, the Investor shall only be required to provide the documents and the legal opinion
attached hereto as Exhibits B-1 and B-2, without material deviation therefrom. 
 26. No Litigation. The General Partner represents
and warrants, as of the date hereof, that to the best of its knowledge there is no legal action, suit, arbitration or other legal or administrative or other governmental investigation, inquiry or proceeding (whether federal, state, local or
foreign), which has not been disclosed in the financial statements of the Partnership or the Partnership’s Private Placement Memorandum (a “Legal Action”) pending or threatened against or affecting (i) the Partnership or any of
its properties or assets or (ii) the General Partner or any of its properties or assets, which, if adversely decided against the Partnership or the General Partner, as the case may be, could reasonably be expected to have a material adverse
effect on the Partnership or the General Partner as a whole. Upon the occurrence of any Legal Action described in the preceding sentence, the General Partner shall provide you written notice within thirty (30) days after such Legal Action has
commenced. 
  

 8 

 27. Governmental Actions. The General Partner represents and warrants, as of the date hereof, that
to the best of its knowledge neither the Partnership, the General Partner, nor any of the Key Persons is or has been the subject of, or a defendant in: (i) an enforcement action or prosecution (or settlement in lieu thereof) brought by a
governmental authority relating to a violation of securities, tax, fiduciary or criminal laws, or (ii) a civil action (or settlement in lieu thereof) brought by investors in a common investment vehicle for violation of duties owed to the
investors. The General Partner covenants that it will notify the Investor within five (5) days after obtaining knowledge thereof, in the event any such action or prosecution is initiated during the term of this investment. 
 28. Facsimile Notices. The General Partner agrees to deliver hard copies, personally delivered or deposited prepaid for priority delivery by
nationally recognized courier service, or by U.S. mail of any notices, demand or requests transmitted to the Investor initially via telecopier, email or other similar device. In addition, no Capital Calls will be delivered to the Investor via
telecopier, email or other similar device. 
 29. Default. Notwithstanding anything to the contrary in the Agreement, the Investor
shall not be deemed to have committed any Default under the Agreement unless the General Partner shall have sent the Investor a reminder notice within two (2) calendar days following the date specified for funding in the applicable Capital Call
Notice informing the Investor of its failure to make its required Capital Contribution and the Investor shall have three additional calendar days after the date such notice has been sent to make its Capital Contribution. 
 30. Confidentiality. The General Partner confirms that it will respect Investor’s request not to disclose publicly the name or identity of
Investor except as required by regulatory authority, law or regulation, by legal process, in connection with any tax audit upon reasonable notice to Investor, or as reasonably requested by other investors or prospective investors in the Partnership
or by Subscription Line Lenders or other lenders or prospective lenders to the Partnership. 
 31. Disclosure by Investor.
(a) Investor has advised the Partnership that Investor may be obligated by applicable law to disclose certain public records upon proper request and that information relating to the Partnership or Investor’s investment in the Partnership
may, therefore, be subject to public disclosure unless a specific exemption from such disclosure requirements is available. The Partnership and the General Partner consent to disclosures of information relating to the Partnership as required by
applicable law, provided that Investor agrees to use reasonable efforts to notify the Partnership promptly of any request for information that could reasonably be viewed as possibly leading to public disclosure of information relating to the
Partnership’s or Investor’s investment therein. Investor agrees that the Partnership may pursue any rights it may have under applicable California law to limit the disclosure of such information. Notwithstanding the foregoing, the
Partnership and the General Partner will not have or make any claim against Investor if Investor discloses information relating to the Partnership after determining in good faith that such disclosure is required by law. In no event shall the General
Partner withhold information from the Investor because of its disclosure obligations under the California right-to-know laws and hereby consents to such disclosures. 
  

 9 

 (b) Notwithstanding anything to the contrary contained in the Agreement, the Partnership
and the General Partner hereby agree that (i) Investor shall be permitted to disclose the Applicable Information (as defined below) on its website and generally within materials it publishes containing its investment data and (ii) for the
purposes of this Side Letter agreement “Applicable Information” means: (A) the name of the Partnership, (B) the year in which Investor made its investment in the Partnership, (C) Investor’s capital commitment to
the Partnership and its percentage of ownership in the Partnership, (D) the amount of capital drawn down from Investor by the Partnership, (E) the aggregate amount of distributions to Investor from the Partnership, (F) the property
types owned by the Partnership, (G) the General Partner and (H) such ratios and performance information (calculated by Investor) using the information described in clauses (A)-(E) of this paragraph 31 (b) with respect to
Investor’s investment in the Partnership, including the internal rate of return and the investment multiple. Investor hereby notifies the Partnership and the General Partner that it is required to disclose the Applicable Information on an
annual and regular basis. The Partnership and the General Partner agree that Investor has satisfied its obligations pursuant to paragraph 31(a) with respect to disclosure of the Applicable Information and shall have no obligation to provide
notice of such disclosures under paragraph 31(a). 
 32. Amendments. The General Partner confirms that no amendments will be made
to the Agreement without the consent of the Investor if such amendment would adversely affect Investor’s right to distributions or increase its obligations or liabilities under the Agreement. The General Partner agrees to promptly provide the
Investor with true and correct copies of any and all amendments to the Agreement that are adopted by the Partnership as well as any and all amendments or supplements to the Private Placement Memorandum. 
 33. OFAC/Patriot Act-Compliant Investment. The General Partner hereby confirms that it will use its reasonable efforts to cause the Partnership
not to purchase Investments from, sell Investments to or incur any indebtedness for borrowed money in favor of (i) any Person appearing on the Specially Designated Nationals and Blocked Persons List of the Office of Foreign Assets Control in
the United States Department of the Treasury, (ii) any other Person with whom a transaction is prohibited by applicable provisions of Executive Order 13224, the USA PATRIOT Act, the Trading with the Enemy Act or the foreign asset control
regulations of the United States Treasury Department, in each case as amended from time to time, (iii) any Person known by the Partnership (after reasonable inquiry) to be controlled by any Person described in the foregoing items (i) or
(ii) with ownership of 20% or more of outstanding voting securities being presumptively a control position, or (iv) any Person having its principal place of business located in any country described in the foregoing item (ii), provided
that any purchase or sale of any Investment or any incurrence of indebtedness for borrowed money undertaken by the Partnership prior to the date of this Agreement shall not be subject to this Section 33. For purposes of the foregoing, the
Partnership’s reliance on a representation or warranty made by a counterparty at or prior to the time of a Partnership investment or transaction will constitute reasonable inquiry. The General Partner confirms that the term “Person”
includes governments, territories and other political entities. 
  

 10 

 34. Suspension Mode. The General Partner hereby agrees that, during a suspension of the Investment
Period, it shall not apply any proceeds drawn under any Subscription Line Indebtedness towards an Investment if the General Partner is otherwise precluded from issuing a Capital Call Notice to fund that same Investment. 
 35. Notice of Filing of Petition. The General Partner will notify the Investor immediately if the General Partner or any Key Person files for
bankruptcy protection, or if any petition is filed or proceeding is instituted against any such Key Person under any bankruptcy or insolvency law. 
 36. Foreign Investments. 
 (a) The Partnership will use commercially reasonable efforts to minimize any
withholding tax imposed by any jurisdiction other than the United States on any amounts distributable by the Partnership to the Investor. The General Partner shall assist the Investor to obtain any exemption, exclusion, credit and/or refund
associated with taxation (including but not limited to withholding tax) on any amounts distributable to the Investor (“Exemption”). In addition, the General Partner shall cooperate with and assist the Investor in obtaining necessary
and available information for the Investor to make filings, applications or elections to obtain the Exemption. If and to the extent requested in writing by the Investor, and at the expense of the Investor, the General Partner shall cause such tax
filings, applications or elections to be prepared and filed on the Investor’s behalf with respect to Exemptions from withholding or other tax arising out of the Investor’s Interest. 
 (b) If the Investor is required to file any tax return or report in a jurisdiction outside the United States, solely as a result of the
Investor’s investment in the Partnership, the General Partner and the Partnership shall provide notice as soon as practicable to the Investor and shall cooperate with the Investor in making any such filings. 
 (c) The Partnership shall only invest in a non U.S. investment if, at the time of making such investment, it believes in good faith that
the revenues and capital proceeds arising out of such non U.S. investment may, under applicable law, be remitted out of the applicable foreign jurisdiction in freely convertible currency. 
 (d) The Partnership shall not invest in a non U.S. investment unless such investment is made through an entity which has limited liability
status and which status is recognized as such in the applicable jurisdictions in which the investment will be made, as advised by qualified legal counsel or an internationally recognized certified public accounting firm, with whom the General
Partner shall consult. 
 37. Tax Matters Partner Authority and Obligations. The General Partner, as tax matters Partner of the
Partnership, shall promptly furnish the Internal Revenue Service with information, if any, sufficient to cause the Investor to be treated as a “notice partner” as defined in Section 6231(a)(8) of the Code. The General Partner, as the
tax matters Partner of the Partnership, shall not bind the Investor to a closing agreement or settlement agreement for federal, state, local or foreign tax purposes without Investor’s prior written consent. 
  

 11 

 38. Transactions with Affiliates. The General Partner and Partnership agree that the Partnership
cannot purchase any project within the area of the Four Points project without the prior approval of the Investor. 
 39. Power of
Attorney. The General Partner shall provide the Investor with a copy of any agreement, instrument or other document that is signed by the General Partner as attorney-in-fact for the Investor pursuant to the power of attorney set forth in
Section 15.4 of the Agreement. 
 40. Accountants. The General Partner agrees to send to the Investor an annual report of the
independent public accountant of the Partnership certifying that the allocations of gain and loss of the Partnership and all distributions to the Partners by the Partnership during the preceding fiscal year were made in accordance with the
provisions of the Agreement. 
 41. Exclusive Jurisdiction. To the fullest extent permitted by applicable law, any claim, action or
proceeding by the Investor seeking any relief whatsoever against any Covered Person, or by the General Partner (on behalf of itself or the Partnership) or the Manager seeking any relief whatsoever against the Investor, based on, arising out of, or
in connection with the Partnership Agreement or this letter agreement or the Partnership’s business or affairs shall be brought only in a California State court or Federal court sitting in Sacramento County and not in any other court, except
that any claim, action or proceeding by the Investor as aforesaid may also be brought in a Delaware State court or Federal court sitting in the State of Delaware. 
 42. Capital Contributions. Notwithstanding anything to the contrary in the Partnership Agreement, the Investor shall have no obligation under the Partnership Agreement to make any Capital Contributions prior to
the commencement of the Investment Period. 
 43. Designated Key Person. The Investor hereby confirms the appointment of Steve Todd as
the Designated Key Person; provided that, notwithstanding anything to the contrary in the Partnership Agreement, the General Partner will not appoint a new Designated Key Person unless such Designated Key Person is approved by the Investor, whether
or not the Investor is holding a majority of the LP Percentage Interests at such time. 
 44. Conflicts. This letter agreement
supplements the Agreement and the Subscription Agreement and, to the extent of any conflict between the Agreement, the Subscription Agreement and this letter agreement, the terms hereof shall control with respect to the Investor. 
 45. Closing Documents. Promptly after the Investor’s purchase of an Interest, the General Partner shall provide the Investor’s outside
counsel, Cox, Castle & Nicholson, to the attention of [ ... ]*, with three (3) closing binders containing copies of all closing documents (including, but not limited to, all legal opinions and Side Letters provided to any other
Limited 
  
  
 * Confidential Information (indicated by [...]) has been omitted and filed separately with the Securities and Exchange Commission. 
  

 12 

 
Partner) and a computerized disk containing such documents. The General Partner shall promptly deliver all post-closing amendments to the Agreement, Side
Letters, legal opinions, and any other legal documents to the outside counsel designated in the previous sentence along with an updated computerized disk containing all closing documents. 
 46. Gift Policy. The Investor requires any party who engages in business with the Investor for gain to periodically provide certain disclosures
relating to contributions and gifts. The General Partner hereby acknowledges receipt of the Investor’s Disclosure of Contributions and Gifts Policy attached hereto as Exhibit C-1 (as the same may be revised from time to time, and including all
applicable rules and regulations related thereto, provided that the General Partner has received notice from the Investor of any such revisions, rules and regulations, individually and collectively, the “Policy”). The persons
covered by the Policy are listed on Exhibit C-2 (as the same may be updated from time to time by notice from the Investor to the General Partner, the “Covered Persons”). The information to be provided by the General Partner to the
Investor pursuant to the Policy shall cover the persons affiliated with the General Partner identified on Exhibit C-3 (such persons, which in all cases shall include all Key Persons, are individually and collectively the “Reporting
Persons”). Exhibit C-3 may be updated from time to time by notice from the Investor to the General Partner. 
 Unless notified by
the Investor that the Policy is no longer applicable, the General Partner agrees to provide the information required by the Policy. The Investor shall provide prompt notice to the General Partner of any revision to the Policy, or change in the
Covered Persons or Reporting Persons, and shall cooperate in good faith with the General Partner to explore reasonable means of avoiding a violation of the Policy prior to its occurrence 
 Without limiting the obligation of the General Partner to make inquiry of the Reporting Persons, in the event the General Partner inadvertently failed to
disclose any information that was required to be disclosed pursuant to the Policy, then the General Partner shall have thirty (30) days from the date the General Partner first became aware of such failure to remedy such breach of the Policy

 The Investor acknowledges and agrees that the cost of attendance at meetings of the Advisory Committee or annual or other periodic
meetings of the Partnership or the Limited Partners borne by the Partnership or the General Partner, including but not limited to the cost of any travel, accommodations, materials, meals, or refreshments provided on a non-discriminatory basis to
Limited Partners or members of the Advisory Committee, shall not be deemed to violate the Policy or require any notice by the General Partner pursuant to the Policy 
 In the event that (i) the General Partner fails to timely provide the information required by the Policy to the Investor, or (ii) there is a violation of the Policy by the Partnership or the General Partner,
then, in either such case, the Investor may, at its option, disqualify the Partnership, the General Partner, the Reporting Persons, and their respective affiliates from entering into any future transactions with the Investor for a period of up to
two (2) years. 
 The execution and delivery of this letter agreement by the General Partner constitutes the representation that the
General Partner is authorized under the Agreement to execute and deliver this letter agreement. This letter agreement shall be governed and construed in accordance with the laws of the State of Delaware and all rights and remedies shall be governed
by such laws, without regard to principles of conflict of laws. 
  

 13 

 If the foregoing correctly sets forth your understanding, please execute this Agreement in the space
provided below. 
 This letter may be executed in counterparts, each of which shall be deemed to be an original and all of which, taken
together, shall constitute one and the same instrument. 
 Very truly yours, 
 THOMAS HIGH PERFORMANCE GREEN FUND, L.P. 
 By: Thomas HPGF-GP, LLC, its general partner 
 By: _/s/ James A. Thomas 
 Name: James A. Thomas 
 Title: Chief Executive Officer and President 
 ACKNOWLEDGED AND AGREED, with respect 
 to
paragraph 11(e) hereof, as of the date first written 
 above. 
 THOMAS PROPERTIES GROUP, INC. 
 By: _/s/ James A. Thomas 
 Name: James A. Thomas 
 Title: Chief Executive Officer and President 
 AGREED TO
AND ACCEPTED: 
 CALIFORNIA STATE TEACHERS’ 
 RETIREMENT
SYSTEM 
 By: _/s/ Christopher J. Ailman 
 Name:
Christopher J. Ailman 
 Title: Chief Investment Officer 
  

 Exhibit A 
 Side Letters 
  

 A-1 

 Exhibit B-1 
 Investor Consent 
 FORM OF SUBSCRIPTION CONFIRMATION LETTER 
 ___________, 2007 
 Bank of America, N.A., as Administrative Agent

  
  
  
  
  
  
 Attention:
                                        
   
  

	 	Re:	$___________ revolving credit facility (the “Facility”) evidenced by that certain [Revolving Credit Agreement] (as the same may be modified, amended, or
restated from time to time, the “Credit Agreement”), entered into or to be entered into by and among Thomas High Performance Green Partnership, L.P., as borrower (the “Partnership”), ____________, as
administrative agent (“Administrative Agent”), and the lenders named therein (each, a “Lender”) 

 Ladies and Gentlemen: 
 The purpose of this letter is to confirm to you the status of our involvement in the Partnership and to
consent to, and acknowledge, certain aspects of the Facility. 
 We have entered into the Limited Partnership Agreement of the Partnership
dated as of ______________ (as it may be amended, restated, supplemented, or otherwise modified from time to time, the “Partnership Agreement”), pursuant to which we have (i) acquired an interest in the Partnership; and
(ii) committed to fund capital calls of the Partnership in the aggregate amount not to exceed $__________ (the “Capital Commitment”). Capitalized terms used herein and not otherwise defined shall have the meaning
ascribed thereto in the Partnership Agreement. 
 To date, $________ of our Capital Commitment has been “called,” of which
$__________ has been funded. $____________ of our Capital Commitment remains to be drawn upon the delivery of one or more Contribution Requests or Subscription Capital Calls pursuant to and in accordance with the Partnership Agreement. 

We hereby acknowledge and confirm that we will deliver to you, upon the request of the General Partner, a certificate setting forth the remaining
amount of our Capital Commitment which we are obligated to fund (the “Unfunded Capital Commitment”). 
  

 B-1-1 

 We hereby acknowledge and confirm to you that under the terms of and subject to the limitations and
conditions set forth in the Partnership Agreement, we are and shall remain obligated to fund our Unfunded Capital Commitment required on account of Contribution Requests or Subscription Capital Calls duly made in accordance with the terms of the
Partnership Agreement [IF APPLICABLE IN MULTI-INVESTOR FUNDS: (including, without limitation, those required as a result of the failure of any other Partner to advance funds with respect to a Contribution Request or Subscription Capital Call
duly made)], without setoff, counterclaim or defense of any kind, including any defense arising under Section 365(c) of the U.S. Bankruptcy Code (but without prejudice to our right to assert such claim in one or more separate actions).

 We hereby (i) consent to the pledge by the Partnership to Administrative Agent, for the benefit of Lenders, of the right to call and
receive all Additional Contributions and payments of any and all other portion of our Unfunded Capital Commitment in accordance with the terms of the Partnership Agreement to secure all loans made under the Facility (collectively, the
“Loans”); (ii) represent and warrant that, to our knowledge, as of the date hereof, there is no default, or circumstance which with the passage of time and/or notice would constitute a default under the Partnership
Agreement, which would constitute a defense to, or right of offset against, our obligation to fund our Unfunded Capital Commitment or otherwise reduce our Unfunded Capital Commitment, and to our knowledge, as of the date hereof, there is no defense
to, or right of offset against, our obligation to fund our Unfunded Capital Commitment; (iii) represent and warrant that the Partnership Agreement has been duly executed and delivered by us and constitutes our valid and binding obligation, and
is enforceable against us in accordance with its terms, subject to applicable bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other laws affecting creditors’ rights generally from time to time in effect and to
general principles of equity; (iv) agree that, for so long as the Facility is in place, we and the General Partner shall not amend, modify, supplement, cancel, terminate, reduce or suspend any of our obligations under the Partnership Agreement
without your prior written consent; and (v) agree that, for so long as the Facility is in place, all payments made by us under the Partnership Agreement will be made by wire transfer to the following account which the Partnership has also
pledged as security for the Loans: 
 Bank:
                            Bank of America, N.A. 
 Account Number:         _______________ 
 ABA Number:               _______________ 
 Reference:                    _______________ 

Attention:                     
_______________ 
 We hereby agree that for so long as the Credit Agreement is in effect, we shall, under the terms and subject to the
limitations and conditions set forth in the Partnership Agreement, honor any Contribution Request or Subscription Capital Call with respect to the Partnership delivered to us in the name of the Administrative Agent, without setoff, counterclaim or
defense of any kind, including any defense arising under Section 365(c) of the U.S. Bankruptcy Code (but without prejudice to our right to assert such claim in one or more separate actions), by funding the Additional Contribution of our
Unfunded Capital Commitment into the above account, provided that such Contribution Request or Subscription Capital Call is delivered for purposes of paying due and payable obligations of the Partnership under the Facility, including without 

  

 B-1-2 

 
limitation, those Contribution Requests or Subscription Capital Calls made as a result of the failure of any other Partner to make an Additional Contribution
with respect to a Contribution Request or Subscription Capital Call. Nothing herein shall limit our obligation to honor any Contribution Request or Subscription Capital Call with respect to the Partnership delivered to us in the name of the
Administrative Agent after the occurrence of an “Event of Default” under the Partnership Agreement, which obligation shall remain in full force and effect for so long as the Credit Agreement is in effect. 
 We hereby acknowledge and confirm to you the following: (i) notwithstanding any reference in the Partnership Agreement made to a single Contribution
Request or Subscription Capital Call, we will honor one or more such Contribution Requests or Subscription Capital Calls for the purpose of repayment of the Facility (otherwise on the terms of and subject to the conditions set forth in the
Partnership Agreement); (ii) the requirements of Section 4.07(a) of the Partnership Agreement do not apply to the Facility; (iii) to the extent required pursuant to Section 4.02(a) to permit Capital Contributions to repay the
Facility, such Capital Contributions shall be deemed to be in compliance with all Partnership Plans; (iv) Section 4.07(d)(iv)(1) of the Partnership Agreement shall not apply in respect of amounts advanced under the Facility to Borrowers
other than the Partnership; and (v) Section 4.07(d)(iv)(2) shall not apply in respect of the repayment and retirement of any amounts advanced pursuant to the Facility to Borrowers other than the Partnership, or for purposes of calculation
of the principal amount set forth in the proviso to such Section; and (v) in respect of Contribution Requests or Subscription Capital Calls necessary to repay amounts advanced pursuant to the Facility, we will not exercise remedies arising
pursuant to the first sentence of Section 10.02 of the Partnership Agreement. 
 We also acknowledge that because you and each Lender
will be relying upon the statements made herein in connection with making the Facility available to the Partnership, for so long as the Facility is in place, payments of Additional Contributions of our Unfunded Capital Commitment that we make under
the Partnership Agreement will not satisfy our obligation to fund our Unfunded Capital Commitment unless such contributions are paid into the above account. We hereby acknowledge and agree that the terms of the Credit Agreement and of each loan
document delivered in connection therewith (collectively, the “Loan Documents”) can be modified without further notice to us or our consent; provided, however, that in no event shall any modification of the Credit Agreement
or any Loan Document alter our rights or obligations under the Partnership Agreement or this confirmation without our written consent. We hereby further acknowledge and agree that you and/or any of the Lenders may assign all or part of your or their
rights under this confirmation to any assignee of your/their rights under the Credit Agreement and the Loan Documents, and that this confirmation will remain in effect until we are notified by you that the Facility has been terminated, which
notification you agree to deliver to us at our address(es) for notices set forth in the Partnership Agreement. 
 Anything contained in the
Credit Agreement, any of the Loan Documents, this confirmation, the Partnership Agreement or any other agreement to the contrary notwithstanding, this confirmation is being given on the condition that, and by funding the Facility the Administrative
Agent and Lenders will be deemed to have agreed that, if the Administrative Agent or any Lender exercises any right or remedy under this confirmation or the Partnership Agreement, including, without limitation, any right to call or receive all or
any portion of our Unfunded Capital Commitment, then no new Loans or other advances or draws may be made, 

  

 B-1-3 

 
and no new letters of credit may be issued, under the Facility without our prior written consent, and we shall have no obligation or liability under the
Partnership Agreement, this confirmation or otherwise with respect to any such new Loans or other advances or draws made, or letters of credit issued, under the Facility without our prior written consent. 
 You agree to keep confidential all non-public information about us provided to you pursuant to the Partnership Agreement or the Facility that is
designated confidential; provided however, that nothing herein shall prevent you from disclosing any such information: (a) to any Lender that participates in the Facility or any Affiliate of any Lender; (b) to any assignee, participant or
prospective assignee or participant which has agreed in writing to comply with the provisions of this paragraph; (c) to the employees, directors, agents, attorneys, accountants, rating agency and other professional advisors of any Lender,
assignee, participant, prospective assignee or participant or their respective Affiliates; (d) upon the request or demand of any governmental authority having or asserting jurisdiction over you or any Lender; (e) in response to any order
of any court or other governmental authority or as may otherwise be required pursuant to any requirement of law; (f) if requested or required to do so in connection with any litigation or similar proceeding; (g) which has been publicly
disclosed other than in breach of this paragraph; (h) in connection with the exercise of any remedy under the Credit Agreement or any other Loan Document; or (i) upon the advice of counsel that such disclosure is required by law.

  

 B-1-4 

 We acknowledge and agree that each of the Partnership Agreement and this confirmation constitutes a
contract within the meaning of Cal. Gov. Code Section 814. 
 This letter is given exclusively for the benefit of the Administrative
Agent and the Lenders. This letter shall not be deemed to confer any rights upon, nor obligate the undersigned to, any person or entity not a party to this letter, including without limitation the Borrower, any Partner of the Borrower or the General
Partner. 
 [IF APPLICABLE: This letter supercedes in their entirety any and all prior letters (the “Prior Letters”)
executed by the undersigned in connection with the Facility or Credit Agreement, any predecessor to the Facility or Credit Agreement, or any prior facility or credit agreement among the Partnership, the Agent, the Lenders party thereto, or any of
them. As of the date hereof, any Prior Letter not previously rendered ineffective shall have no further force or effect.] 
 CALIFORNIA STATE TEACHERS’ 
 RETIREMENT SYSTEM, 
 a public entity 
 By: _/s/ [name]_____________________________ 
 Name:                                     
                                        

Title:                                     
                                         

  

 B-1-5 

 Exhibit B-2 
 Legal Opinion 
 FORM OF SUBSCRIPTION LEGAL OPINION 
 ___________, 200__ 
 Bank of America, N.A., as Administrative Agent

  
  
  
  
  
  
  

	Re:	Thomas High Performance Green Partnership, L.P. (the “Partnership”) 

 Ladies and Gentlemen: 
 I have acted as counsel for California State Teachers’ Retirement System, a
public entity (the “Investor”), in connection with the matters addressed herein. This opinion is being prepared and is being delivered to you at the direction of the Investor. 
 I have examined originals, or copies certified or otherwise identified to my satisfaction, of such documents, corporate records, and other instruments as
I have deemed necessary or appropriate for the purposes of this opinion, including the following: 
  

	 	(a)	the Limited Partnership Agreement of Partnership dated as of _____________[, as amended] (the “Partnership Agreement”); and 

  

	 	(b)	the Confirmation Letter (the “Confirmation Letter”) dated as of _________, 2007 entered into by Investor in connection with that certain [Revolving Credit
Agreement] entered into or to be entered into by and among the Partnership, the lenders named therein, and Bank of America, N.A., as administrative agent for the benefit of the lenders (the “Credit Agreement”).

 Based on the foregoing, I am of the opinion that: 
  

	 	1.	The Investor is the State Teachers’ Retirement System established pursuant to Title I, Division 1, Parts 13 and 14 of the California Education Code, Section 22000, et.
seq., as amended. California Education Code Section 22001 and California Government Code Section 12804 provide that CalSTRS is a unit of the State and Consumer Services Agency. California Government Code Section 12800 provides that the
State and Consumer Services Agency is an agency in the state government of California. 

  

 B-2-1 

	 	2.	The Partnership Agreement and the Confirmation Letter have been duly authorized, executed and delivered by the Investor. 

 The opinions herein are limited to the laws of the State of California and the federal laws of the United States of America, and I express no opinion on
the effect on the matters covered by this opinion of the laws of any other jurisdiction. 
 This opinion is rendered solely for the benefit
of the addressee hereof and the Lenders under the Credit Agreement, and their successors and assigns in connection with the transactions described above. This opinion may not be used or relied upon by any other person or by you for any other purpose
and may not be disclosed, quoted, filed with a governmental agency or otherwise referred to without my permission. 
 Very
truly yours, 
 [ ... ]* 
 [ ... ]* 
  

 B-2-2 

 Exhibit C-1 
 Disclosure Of Contributions And Gifts 
  

	1.	Any party who “engages in business with CalSTRS for gain” shall disclose the following: Campaign contributions as defined under the Political Reform Act, valued in excess
of $250, made to any official covered in section 3 of this policy. 

  

	2.	No party who “engages in business with CalSTRS for gain” shall provide gifts to Board members or to CalSTRS Staff, as follows: 

  

	 	A.	Any charitable contribution, valued in excess of $250 individually or in the aggregate in any calendar year, made at the request of any official covered in this section.

  

	 	B.	Gifts, meals, or entertainment, with a cumulative value equal to or exceeding $390 individually or in the aggregate in any calendar year, given to any official covered in this
section. 

 This prohibition shall not extend to meals or related expenses provided under the following circumstances:

  

	 	(i)	Food, beverages and registration at group events to which substantial numbers of employees of an institution are invited; 

  

	 	(ii)	Actual and reasonable expenses for food, beverages, travel, lodging and/or registration provided to permit participation in a meeting directly tied to official or professional
duties if participation has been approved in writing by the Chief Executive Officer (for CalSTRS staff) or by the CalSTRS Board (for Board members). 

  

	3.	This Policy shall apply to campaign contributions that are made to or on behalf of any existing CalSTRS Board member and candidates for Board member, Controller, Treasurer, and
Superintendent of Public Instruction, or CalSTRS staff and to campaign contributions made to the Governor or candidates for the governorship. 

  

	4.	This policy shall apply to any vendor, investment firm, consultant, any other nongovernmental entity, including their partners, executive officers, and third party solicitors as
specified in Section 600 J, and contributions or gifts from others made at the direction of the entity or these identified individuals which either (1) seeks a business relationship with the System or (2) has a current relationship
with the System, which is likely to generate at least $100,000 annually in income, fees or other revenue to the business entity. This policy shall also apply to any business relationship with the System that will be considered in a closed session of
the Board or a committee thereof. 

  

	5.	Disclosure of contributions and gifts shall be required as follows: 

  

 C-1-1 

	 	A.	Upon submission of an initial application or proposal to do business with the System (for the preceding 12-month period). 

  

	 	B.	At the time the final decision is to be made regarding the business proposal. (To cover the interim period since the initial application.) 

  

	 	C.	Annually, for the previous calendar year, if the income threshold in section 4 is met. (CalSTRS will use FPPC guidelines to determine which officials in a specific firm must file
disclosure statements.) 

  

	6.	Any violation of this policy may lead to disqualification from doing business with the System for a period of two years. The General Counsel is responsible for investigating any
reported violation and shall report any documented violation to the Board for action. 

  

	7.	Any Board member who receives contributions or gifts that individually or in the aggregate exceed the amount of $250 in a calendar year shall recuse his/herself from any involvement
in a matter involving the maker of the contributions or gifts for a period of 12 months following the date of the most recent contribution or gift. 

  

	8.	Any Board member who returns, donates, or reimburses the donor for gifts subject to the restrictions of section 7 within 30 calendar days of receipt of the gift shall not be subject
to the recusal requirement of section 7. Gifts may be returned, donated or reimbursed as specified in California Code of Regulations, Title 2, Division 6, Chapter 9.5, section 18943. 

  

	9.	Nothing in this policy supersedes any provision of State law. Those entities engaged in business with the System may also have reporting requirements under the Political Reform Act,
California Government Code section 51000 et seq. Also, Board members who are either elected to the Board by a CalSTRS constituency or who are appointed to the Board but also serve as an elected official of a local body are subject to Government Code
section 84308, which prohibits the receipt, solicitation or direction of a campaign contribution of more than $250 while a matter affecting a financial interest of the maker of the contribution is pending, and for three months following the date a
decision is rendered on the matter. Section 84308 also requires recusal of the Board member from any involvement in the matter if a contribution over $250 has been received within the preceding 12 months, unless the contribution was returned no
later than 30 days from the time the Board member knew or should have known about the contribution and the matter involving the maker of the contribution. 

  

 C-1-2 

 Exhibit C-2 
 Disclosure Of Contributions And Gifts 
 [ ...]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ... ]* 
 [ ...
]*                                        
                                [ ... ]* 
 [ ...
]*                                        
                                [ ... ]* 
 [ ...
]*                                        
                                [ ... ]* 
 [ ...
]*                                        
                                [ ... ]* 
 [ ...
]*                                        
                                [ ... ]* 
  
  
 * Confidential Information (indicated by [...]) has been omitted and filed separately with the Securities and Exchange Commission. 
  

 C-2-1 

 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
 [ ...
]*                                        
                                        
                        [ ... ]* 
  
  
 * Confidential Information (indicated by [...]) has
been omitted and filed separately with the Securities and Exchange Commission. 
  

 C-2-2 

 Exhibit C-3 
 Key Personnel at Partnership 
 Key Persons as of December 18, 2008: 
 James A. Thomas 
 Thomas S. Ricci 
 Diana M. Laing 
 Steve Todd 
 Investment Committee as of December 18, 2008: 
 James A.
Thomas, as chairman 
 John R. Sischo 
 Thomas S. Ricci

 Diana M. Laing 
 Randall L. Scott 
  

 C-3-1Supply and Distribution Agreement

 Exhibit 10.61 
 Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. 
 SUPPLY AND DISTRIBUTION AGREEMENT 
 This Supply and Distribution Agreement (this “Agreement”), dated as of the
13th day of October, 2006 (the “Effective Date”), is made by and between Salix Pharmaceuticals, Inc., a California corporation (“Salix”), and Watson Pharma, Inc., a Delaware corporation (“Watson”). 
 WITNESSETH: 
 WHEREAS, Salix has manufactured and distributes in the Territory (as defined herein) 750 mg
capsules of balsalazide disodium under the trademark Colazal®; and 
 WHEREAS,
Watson desires to purchase from Salix, and distribute and sell to certain purchasers in the Territory under the NDA (as defined herein), 750 mg capsules of balsalazide disodium in generic form, and Salix desires to supply such product and grant such
distribution rights, all on the terms and conditions set forth herein. 
 NOW, THEREFORE, in consideration of the agreements and covenants
contained herein, the receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally bound, hereby agree as follows: 
 ARTICLE 1. DEFINITIONS 
 The following terms as used in this Agreement, whether used in the singular or the plural, shall
have the meanings set forth in this Article 1. References to “Articles”, “Sections” and “subsections” in this Agreement shall be to Articles, Sections and subsections, respectively, of this Agreement unless otherwise
specifically provided. 
 1.1. “Acquisition Notice” shall have the meaning set forth in Section 11.4(b). 
 1.2. “Act” shall mean the United States Federal Food, Drug, and Cosmetic Act as in effect from time to time. 
 1.3. “Affiliate” shall mean, with respect to any Person, any other Person that, directly or indirectly, controls, is controlled by, or is under
common control with, such Person; provided that for purposes of this Agreement, a Wholesaler Affiliate shall not constitute an Affiliate of Watson. For the purposes of this definition, Section 1.53 and Section 11.4, the term
“control”, as applied to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management of such Person, whether through ownership of voting securities or otherwise. 
 1.4. “Agency” shall mean any applicable supra-national, federal, national, regional, state, provincial or local regulatory agency, department,
bureau, commission, council or other government entity regulating or otherwise exercising authority with respect to the Manufacturing, marketing, sale, or distribution of the Generic Product in the Territory. 
 1.5. “Agreement” shall have the meaning given such term in the introductory paragraph hereof. 
  

 1 

 1.6. “ANDA” shall mean an abbreviated new drug application under the Act for balsalazide
disodium, including any amendments or supplements thereto. 
 1.7. “Applicable Laws” shall mean all applicable provisions of
constitutions, statutes, laws, rules, treaties, regulations, guidelines, guidances and orders of all governmental authorities and all applicable orders, rules and decrees of courts and arbitrators in the Territory. 
 1.8. “Authorized Purchasers” shall mean all Third Parties except Excluded Purchasers. 
 1.9. “Average Manufacturer Price” shall have the meaning defined in the Social Security Act, 42 U.S.C. §1396r-8(k). 
 1.10. “Average Monthly Profit” shall mean (a) the aggregate amount of Profits during the six calendar months immediately preceding the
month in which the Acquisition Notice is delivered, divided by (b) six (6). 
 1.11. “Best Price” shall have the meaning
defined in the Social Security Act, 42 U.S.C. §1396r-8(c)(1)(C). 
 1.12. “Branded Product” shall mean 750 mg capsules of
balsalazide disodium in finished, packaged form that is distributed by Salix or its Affiliates in the Territory under the Trademark. 
 1.13.
“Calendar Quarter” shall mean each period of three (3) consecutive months commencing on January 1, April 1, July 1, and October 1. 
 1.14. “Calendar Year” shall mean each twelve (12) month period commencing on January 1 and ending on December 31 in any given
year. 
 1.15. “cGMP” shall mean current Good Manufacturing Practices, as specified in the United States Code of Federal
Regulations (21 CFR Part 210 & Part 211), and any other applicable laws, guidelines and/or regulations. 
 1.16. “Change of
Control” shall mean any of the following events: 
 (a) Watson ceases to be a wholly owned subsidiary of Parent; or 
 (b) any Person or group (as such term is defined in the Securities Exchange Act of 1934, as amended) acquires beneficial ownership of securities of
Parent representing more than fifty percent (50%) of the voting power of the then outstanding securities of Parent with respect to the election of directors of Parent, or 
 (c) Parent enters into a merger, consolidation or similar transaction with another Person in which Parent is not the surviving entity in such
transaction, or 
 (d) Parent enters into a merger, consolidation or similar transaction with another Person in which Parent is the surviving
entity in such transaction but (i) the members of 

  

 2 

 
the Board of Directors of Parent immediately prior to such transaction constitute less than one half of the members of the Board of Directors of Parent
following such transaction or (ii) the Persons who beneficially owned the outstanding voting securities of Parent immediately prior to such transaction cease to beneficially own securities of Parent representing at least fifty percent
(50%) of the voting power of the then outstanding securities of Parent with respect to the election of directors immediately after such transaction in substantially the same proportions as their ownership of securities of Parent immediately
prior to such transaction. 
 1.17. “Commercially Reasonable Efforts” shall mean, with respect to the efforts to be expended by a
party with respect to any objective, reasonable, good faith efforts to accomplish such objective as such party would normally use to accomplish a similar objective under similar circumstances, it being understood and agreed that with respect to the
marketing, distribution and sale of the Generic Product, such efforts shall be similar to those efforts and resources commonly used by Watson in the Territory for similar pharmaceutical products at a similar stage in their product life and of
similar market potential, taking into account the competitiveness of alternative products sold by Third Parties in the marketplace and the profitability of the products. 
 1.18. “Confidential Information” shall have the meaning set forth in Section 12.1. 
 1.19.
“Disclosing Party” shall mean the party disclosing Confidential Information. 
 1.20. “Distribution Period” means the
period commencing on the Launch Date and ending on the last day of the Term. 
 1.21. “Effective Date” shall have the meaning given
such term in the introductory paragraph to this Agreement. 
 1.22. “Equivalent Product” means any product other than Generic
Product, which (a) is manufactured and distributed by a Person pursuant to an ANDA which was approved by the FDA or (b) is otherwise an A-Rated generic version of the Branded Product. 
 1.23. “Excluded Purchasers” shall mean [*]. 
 1.24. “FDA” shall mean the United States Food and Drug Administration or any successor organization in the Territory. 
 1.25. “Firm Order” shall have the meaning set forth in Section 4.2(c). 
 1.26. “Firm
Forecast” shall have the meaning set forth in Section 4.2(b). 
 1.27. “For Cause Incident” shall have the meaning set
forth in Section 7.8. 
 1.28. “Force Majeure” shall have the meaning set forth in Section 13.2. 
 1.29. “Force Majeure Party” shall mean a party prevented or delayed in its performance under this Agreement by an event of Force Majeure.

  

 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 
 3 

 1.30. “Forecast” shall have the meaning set forth in Section 4.2(b). 
 1.31. “Generic Product” shall mean 750 mg capsules of balsalazide disodium in finished, packaged form (which packaging shall bear trade dress
different from the Branded Product) that is Manufactured under the NDA by Salix, its Affiliate or a Third Party designated by Salix, which capsules may have a capsule image different from that of the Branded Product. 
 1.32. “Launch Date” shall mean the date of the first commercial sale in the Territory by any Third Party of a generic version of 750 mg
capsules of balsalazide disodium under an ANDA approved by the FDA. 
 1.33. “Losses” shall have the meaning set forth in
Section 10.1. 
 1.34. “Manufacture” and “Manufacturing” shall mean all activities related to the production,
manufacture, processing, filling, finishing, packaging, labeling, shipping and holding of any pharmaceutical product or any intermediate thereof, including stability testing, quality assurance and quality control. 
 1.35. “Materials” shall mean all active pharmaceutical ingredients, raw materials, excipients, packaging and labeling components, and other
items used to Manufacture Generic Product. 
 1.36. “NDA” shall mean Salix’s new drug application Colazal 20-610 under the
Act, including any amendments or supplements thereto. 
 1.37. “NDC Number” shall mean a unique 3-segment number that identifies
the labeler/vendor, the product and the trade package size. 
 1.38. “Net Sales” shall mean, with respect to any period, the actual
gross amounts invoiced by Watson or its Affiliates on all sales of the Generic Product in the Territory during such period, less deductions actually allowed for by Watson: 
 (a) [*]  
 Net Sales shall be determined on an accrual basis (except for clause (e) above) in accordance
with generally accepted accounting principles in the Territory, applied on a basis consistent with Watson’s annual audited financial statements. Net Sales with respect to sales of the Generic Product that are not made on an arm’s length
basis or that are made for consideration other than cash shall be calculated based on the average per-unit Net Sales of the Generic Product during the applicable period without regard to such non-arm’s length or non-cash sales. If the Generic
Product is sold with other products on a portfolio basis, any discounts or other adjustments with respect to the Generic Product shall be allocated pro rata across all products in such portfolio based on the non-discounted, non-adjusted price for
each such product. For purposes of calculating Net Sales, sales between or among Watson and its Affiliates shall be excluded from the computation of Net Sales. Watson will not deduct any marketing, selling, advertising or distribution expenses of
any kind to determine Net Sales. 
 1.39. “Parent” shall mean Watson Pharmaceuticals, Inc. 
  

 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 

4 

 1.40. “Person” shall mean an individual, sole proprietorship, partnership, limited partnership,
limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political subdivision, department
or agency of a government. 
 1.41. “Profits” shall mean, with respect to any period, Net Sales during such period, less the
Purchase Price for the Generic Product sold during such period paid by Watson hereunder. 
 1.42. “Purchase Price” shall have the
meaning set forth in Section 5.1. 
 1.43. “Receiving Party” shall mean the party receiving Confidential Information.

 1.44. “Recipient” shall have the meaning se forth in Section 12.1. 
 1.45. “Salix Indemnitees” shall have the meaning set forth in Section 10.1. 
 1.46. “Specifications” shall mean the final release quality specifications for the Generic Product as set forth on Exhibit A, as the same may
be amended from time to time in accordance with this Agreement. 
 1.47. “Term” shall have the meaning set forth in
Section 11.1. 
 1.48. “Territory” shall mean the fifty states of the United States of America, the District of Columbia, the
Commonwealth of Puerto Rico, and all other territories, possessions and commonwealths of the United States of America. 
 1.49. “Third
Party” shall mean any Person other than Salix, Watson, or their respective Affiliates. 
 1.50. “Trademark” shall mean Colazal®. 
 1.51. “Watson
Indemnitees” shall have the meaning set forth in Section 10.2. 
 1.52. “Whole Lots” shall have the meaning set forth in
Section 4.3. 
 1.53. “Wholesaler Affiliate” shall mean any Person (a) that, directly or indirectly, controls, is
controlled by, or is under common control with, Watson and (b) substantially all of the business of which consists of the wholesale distribution of pharmaceutical products. 
 ARTICLE 2. DISTRIBUTION RIGHTS AND OBLIGATIONS 
 2.1. Authorized
Distributor. Salix hereby appoints Watson to market, distribute, offer for sale and sell the Generic Product to Authorized Purchasers in the Territory under the NDA during the Distribution Period [*], and Watson hereby accepts such
appointment. Watson acknowledges and agrees that until the Launch Date, Watson shall have no right to distribute, market, sell or accept orders for the sale of the Generic Product, except that Watson may engage in pre-booking activities of the type
described in Exhibit B. 
  

 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 

5 

 2.2. Commercially Reasonable Efforts. 
 (a) Watson shall use Commercially Reasonable Efforts to market, sell, and distribute the Generic
Product to Authorized Purchasers in the Territory during the Term. Watson shall not use the Trademark or any other trademark or tradename similar to the Trademark on, or in connection with the marketing, sale, or distribution of, the Generic
Product; provided, however, that Watson may use the Trademark in Watson’s advertising and promotional materials in accordance with Section 2.9 solely to identify the Generic Product as comparable to Branded Product and to identify
Salix as the owner of the Trademark associated with the Branded Product (e.g., “Balsalazide Disodium Capsules – Compare to Colazal®. Colazal® is a registered trademark of Salix Pharmaceuticals, Inc.”). 
 (b) Salix hereby grants to Watson a
non-exclusive, non-sublicensable, royalty-free license to use the Trademark solely for the purposes set forth in Section 2.2(a), which license shall terminate upon the expiration or termination of this Agreement. During the Term and thereafter,
Watson shall not in any event register or, in connection with the sale of the Generic Product or any Equivalent Product, use any trademark which, in the reasonable opinion of Salix is confusingly similar to the Trademark. Watson shall not use the
Trademark in any manner whatsoever which may jeopardize the significance, distinctiveness or validity thereof, and Watson shall give prompt written notice to Salix of any infringement, by any person, of the rights of Salix in the Trademark which
come to Watson’s notice. Watson acknowledges and agrees that all right, title and interest in and to the Trademark shall at all times remain the exclusive property of Salix and all use of the Trademark hereunder shall inure to the benefit of
Salix. Watson hereby recognizes the validity of the Trademark and the registrations thereof, and will not, during the Term or thereafter, contest the validity thereof. For the avoidance of doubt, no license is granted hereby to use the Trademark in
connection with any Equivalent Product. 
 2.3. Compliance with Law. Watson shall (a) store, handle and distribute the Generic
Product in clean and sanitary conditions as required to maintain the quality and traceability of the Generic Product, (b) not alter the Generic Product in any manner, including the labeling and packaging thereof (c) comply with cGMP and
all other Applicable Laws in connection with the storage, handling, distribution, marketing and sale of the Generic Product, including applicable recordkeeping obligations, (d) not market the Generic Product in any manner which is inconsistent
with the labeling of the Generic Product or Applicable Laws, or otherwise make any false or misleading representations to customers or others regarding the Generic Product. 
 2.4. No Sales Outside Territory or to Excluded Purchasers. Watson shall not, and Watson shall cause its Affiliates not to, (a) sell any
Generic Product to, or solicit orders for sales of any Generic Product from, any existing or prospective customer outside the Territory or any Excluded Purchaser, (b) deliver or tender (or cause to be delivered or tendered) any Generic Product
outside the Territory or to any Excluded Purchaser, or (c) sell any Generic Product to, or solicit any sales from, a customer in the Territory if Watson knows or should know that such customer intends to resell the Generic Product outside the
Territory. 
  

 6 

 2.5. Pricing. Watson shall have sole discretion to establish the prices and terms on which Watson
sells the Generic Product. 
 2.6. Reserved Rights. Except as expressly provided in this Agreement, no right, title or interest in, to
or under the NDA or any patent, trade secret, trademark or any other intellectual property right of Salix or its Affiliates is granted, whether express or implied, by Salix to Watson. In furtherance of the foregoing and not in limitation thereof,
nothing herein shall in any way limit the Manufacturing, marketing, selling or distributing of the Branded Product by Salix or its Affiliates (directly or through a Third Party) anywhere in the world. 
 2.7. NDC Number. Watson shall submit drug listing information to the FDA with respect to the Generic Product. Watson shall distribute and sell
only Generic Product bearing an NDC Number that reflects Watson as the distributor and seller thereof. Within fourteen (14) days after the Effective Date, Watson shall obtain an NDC Number for each packaging configuration of the Generic Product
set forth on Exhibit D. 
 2.8. Rebate Processing. 
 (a) Watson shall be solely responsible for all federal, state and local government and private purchasing, pricing or reimbursement programs with respect to the Generic Product sold by Watson, including taking all
necessary and proper steps to execute agreements and file other appropriate reports and other documents with governmental and private entities. Watson shall be solely responsible for payment and processing of all rebates, whether required by
contract or local, state or federal law, for the Generic Product sold by Watson. 
 (b) Watson agrees to provide all information and data
that Salix reasonably requests in order to comply with any state or federal government price reporting requirements for the Branded Product. Watson’s obligation under this Section 2.8(b) may include, but shall not be limited to, providing
aggregate sales and rebate transaction data, Average Manufacturer Price and Best Price calculations, other data or information regarding sales or pricing (both on and off-invoice) of the Generic Product by Watson necessary for the government
submissions, as determined by Salix in its reasonable discretion. Watson further agrees to provide such information within twenty (20) days of the close of each Calendar Quarter, or such sooner time period as may be necessary to permit Salix to
satisfy its obligations in a timely manner. Watson warrants that all information provided to Salix pursuant to this Section 2.8(b) will be complete and accurate in all material respects. Salix may use any information provided pursuant to this
Section in Salix’s reporting to the Centers for Medicare and Medicaid Services or other Federal and state authorities. In the event that Watson discovers, through a routine audit, reconciliation, its compliance program or otherwise, that any
government price reporting has been miscalculated or other data provided to Salix regarding the sales or pricing of the Generic Product in the Territory are inaccurate, Watson shall notify Salix immediately of such circumstance and shall work with
Salix to ensure that proper pricing information is provided to Salix as soon as possible, but in no event later than thirty (30) days after the end of the quarter in which such inaccuracy is discovered. Watson further agrees that it will
provide any information reasonably requested by Salix pertaining to its methodologies for calculating government price reporting for the Generic Product. Notwithstanding the foregoing, in no event shall Salix be 

  

 7 

 
liable for any mistakes, errors, omissions or other inaccuracies in Watson’s pricing methodologies. The parties agree that any pricing data provided by
Watson pursuant to this Section 2.8(b) shall be used for the limited purpose of complying with legal price reporting requirements and shall not in anyway be used for “price fixing” or similar anti-competitive behavior by either party.
Watson has and will maintain during the Term an effective compliance program based on the Office of Inspector General Compliance Program Guidance for Manufacturers. 
 2.9. Promotional Materials. Watson shall not use any promotional materials in connection with the marketing, sale or distribution of the Generic Product without Salix’s prior written approval other than
(a) the labeling for the Generic Product approved by Salix in accordance with Section 4.6 and (b) after the Launch Date, introduction announcements to the trade, bill sheets and Watson’s on-line product catalog; provided that any
such promotional materials shall not contain any information other than the name of the Generic Product, the available packaging configurations, and pricing and delivery terms. For purposes of this Agreement, “promotional materials” means
all labeling and advertising materials as defined in the Act and the regulations of the FDA thereunder. 
 2.10. Sampling. Watson
shall not distribute any samples of Generic Product to any Third Party. 
 2.11. No Subcontracting or Subdistribution. All obligations
and services to be performed by Watson under this Agreement shall be solely performed by Watson (or its Affiliates, in which event Watson shall cause any such Affiliate to comply with all the terms and conditions in this Agreement as if named as a
party hereto) and Watson shall not outsource or subcontract any of its obligations hereunder. Watson itself shall directly market, offer for sale, and sell the Generic Product to the trade (including, without limitation, pharmaceutical wholesalers
and retailers) in the Territory and Watson shall not market, offer for sale, or sell the Generic Product to the trade (including, without limitation, pharmaceutical wholesalers and retailers) through or by means of any Third Party without the prior
written consent of Salix. Watson covenants and warrants that all sales of Generic Product by Watson or its Affiliates to Wholesaler Affiliates shall be made on arm’s length terms and conditions. 
 2.12. [*]  
 ARTICLE 3.
PROFIT SHARE 
 3.1. Profit Share. 
 (a) Watson shall pay to Salix, in accordance with Section 3.2, an amount equal to [*] percent ([*]%) of the positive Profits for each calendar month during the Term and any selloff
period under Section 11.9 after the Term. [*]. An example of the calculation of the sharing of Profits pursuant to this Section 3.1, for illustration purposes only, is attached as Exhibit E. 
 (b) If, during any month during the Term occurring during the first twelve (12) months after the Launch Date (the “First Year”) there are
two (2) or more Equivalent Products being distributed under separate ANDAs concurrently, then, to the extent Profits are 

  

 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 

8 

 
negative in such month in the First Year, Salix shall reimburse Watson for [*] percent ([*]%) of the amount of such negative
Profits within sixty (60) days after the end of such calendar month; provided that, at Salix’s option, such amount may be credited against future Profits payable by Watson to Salix hereunder if, and to the extent, there are future
positive Profits. If Profits are negative at any time during the Term, the parties shall cooperate in good faith to attempt to minimize potential losses to each party; provided that in no event shall either party be obligated to amend this
Agreement. 
 3.2. Reporting and Payment. Not later than forty-five (45) days after the end of each calendar month through and
including the calendar month in which all rebate and chargeback amounts on Generic Product sold during the Term and any applicable selloff period under Section 11.9 are finally reconciled in accordance with Section 1.38, Watson shall:

 (a) deliver to Salix a written report substantially in the form attached as Exhibit G that specifies the Net Sales and Profits with respect
to such calendar month; and 
 (b) pay to Salix the amount owed to Salix with respect to such calendar month in accordance with
Section 3.1. 
 3.3. Maintenance of Records; Audit. Watson shall maintain, and shall cause its Affiliates to maintain, at a
location in the United States, complete and accurate books and records in such detail as is necessary to accurately calculate the amounts payable to Salix under Section 3.1. Such books and records shall be maintained for a period of at least
five (5) years after the end of the Calendar Year in which they were generated, or for such longer period as may be required by Applicable Law. Once per each Calendar Year during the period commencing on the Effective Date and ending
twenty-four (24) months after the end of the Calendar Quarter in which all rebate and chargeback amounts on Generic Product sold during the Term and any applicable selloff period under Section 11.9 are finally reconciled in accordance with
Section 1.38, Salix shall have the right to have an independent accounting firm reasonably acceptable to Watson audit and examine the relevant books and records as may be reasonably necessary to determine and/or verify the amount of payments
due hereunder and Watson’s compliance with its obligations hereunder. Such audit and examination shall be conducted and shall take place, and Watson shall, and shall cause its Affiliates to, make such books and records available, during normal
business hours at the facility(ies) where such books and records are maintained. Each such audit and examination shall be limited to pertinent books and records for any Calendar Year ending not more than twenty-four (24) months prior to the
date of the audit. Before permitting such independent accounting firm to have access to such books and records, Watson may require such independent accounting firm and its personnel involved in such audit to sign a customary confidentiality
agreement in form and substance reasonably acceptable to Watson as to any Confidential Information which is to be provided to such accounting firm or to which such accounting firm will have access while conducting the audit under this
Section 3.3. The independent accounting firm will prepare and provide to Salix and Watson a written report stating only whether the reports submitted and amounts paid pursuant to Section 3.2 were correct or incorrect, and the amounts of
any discrepancies. Prior to disclosing the results of any such audit, the auditor shall present Watson with a preliminary report of its findings and provide Watson with an opportunity to respond to any questions raised or issues identified. In the
event that there was an underpayment or overpayment by Watson hereunder, Watson or Salix, as the 

  

 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 

9 

 
case may be, shall promptly (but in no event later than thirty (30) days after its receipt of the independent accountant’s report so concluding)
make payment to the other of the amount of such underpayment or overpayment. Salix shall bear all costs and expenses of any such audit, except that if any audit discloses an underpayment or overpayment by Watson with respect to any Calendar Year in
excess of the lesser of (i) [*] percent ([*]%) of the aggregate amount required to be paid under Section 3.1 and (ii) [*] dollars ($[*]), all costs and expenses of the audit,
including the expenses of the independent accounting firm, shall be borne and promptly paid by Watson. 
 ARTICLE 4. PRODUCT SUPPLY 

 4.1. [*] Supply. Subject to the terms and conditions of this Agreement, Salix agrees to supply, or cause its
Affiliate or a Third Party to supply, to Watson during the Term, and Watson agrees to purchase from Salix, Salix’s Affiliate or such Third Party, as the case may be, [*] of Watson’s requirements of the Generic Product. Salix,
in its sole discretion, shall determine whether to Manufacture the Generic Product or to have an Affiliate of Salix or Third Party Manufacture Generic Product. 
 4.2. Forecasting and Orders. 
 (a) Watson acknowledges and agrees that all forecasts and Firm Orders
shall be subject to the maximum monthly Whole Lot quantities set forth in Exhibit C attached hereto. 
 (b) At least [*]
([*]) days prior to the first day of each Calendar Quarter during the Term commencing with the Calendar Quarter in which the expected Launch Date occurs, Watson shall deliver to Salix a written good faith forecast estimating the
quantities of Generic Product that Watson expects to purchase from Salix during such Calendar Quarter and the following three (3) Calendar Quarters, broken out on a monthly basis (each a “Forecast”). The first Calendar Quarter of each
Forecast shall be a “Firm Forecast.” Except as provided in Section 4.2(c), each Forecast shall be non-binding and shall be used by Salix for planning purposes only. 
 (c) At least [*] ([*]) days prior to the first day of each Calendar Quarter during the Term commencing with the Calendar
Quarter in which the expected Launch Date occurs, Watson shall submit to Salix a written purchase order in such form as shall be reasonably acceptable to Salix (a “Firm Order”) for the quantity of Generic Product to be delivered to Watson
during each month of such Calendar Quarter, which Purchase Order shall specify the required delivery date for such Generic Product. The quantity of Generic Product specified in any Purchase Order for delivery in any month of a Calendar Quarter shall
not be less than [*] percent ([*]%) of, nor more than [*] percent ([*]%) of, the quantities specified in the Firm Forecast applicable to such month. In the event Salix fails to timely deliver
Generic Product ordered hereunder, Watson may revise its Forecasts, including any Firm Forecast, to address the shortfall of supply and/or the impact such late delivery may have had on the trade for Generic Product, and Salix shall use Commercially
Reasonable Efforts to accommodate such revisions. 
 (d) If any Generic Product purchased by Watson prior to the Launch Date has less than
sixteen (16) months remaining before its expiration date, and the Launch Date has not 

  

 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 

10 

 
occurred, Watson may return such Generic Product to Salix and Salix shall use Commercially Reasonable Efforts to replace promptly such returned Generic
Product with Generic Product with expiration dating greater than twenty (20) months at no additional cost. In the event the Parties determine that it is likely that Watson will have to return Generic Product pursuant to this
Section 4.2(d), the Parties will use Commercially Reasonable Efforts to assure that such replacement Generic Product shall be available by the Launch Date. 
 4.3. Whole Lots. Watson shall order and forecast all quantities of Generic Product only in whole batch size increments of approximately [*] capsules (“Whole Lots”); provided that Watson
acknowledges and agrees that unit quantities in Whole Lots may vary from time to time due to discards and yield variances. At the time of delivery, all Generic Product delivered hereunder shall have a minimum of twenty-four (24) months
remaining on the expiry schedule for the Generic Product as specified in the NDA. 
 4.4. Firm Orders. Subject to Article 11, Watson
shall be obligated to purchase, and Salix shall be obligated to deliver by the required delivery date set forth therein, such quantities of Generic Product as are set forth in each Purchase Order. In the event that the terms of any Purchase Order
are not consistent with or are in addition to the terms of this Agreement, the terms of this Agreement shall prevail. 
 4.5.
Delivery. Salix shall deliver, or arrange for delivery of, all Generic Product purchased by Watson hereunder CIP (as defined in Incoterms 2000) a single distribution facility of Watson in the United States. Title to and risk of loss of all
Generic Product sold hereunder shall pass to Watson upon delivery to the carrier. Salix shall include, or cause to be included, the following with each shipment of Generic Product: (a) Watson purchase order number, (b) the batch numbers
for the Generic Product included, (c) the quantity of the Generic Product included, (d) a Certificate of Analysis (the content of which will be outlined in the Quality Agreement) and (e) a Certificate of Compliance (the content of
which will be outlined in the Quality Agreement). 
 4.6. Packaging Configuration. Within five (5) days after the Effective Date,
Salix shall supply Watson with Salix’s labeling for the Branded Product. Within fourteen (14) days after Watson’s receipt of such labeling, Watson shall provide to Salix proposed camera ready artwork for the labeling and packaging for
the Generic Product which shall be consistent with the labeling and packaging of the Branded Product; provided that the labeling and packaging for the Generic Product shall have appropriate references to Watson and the NDC Numbers obtained pursuant
to Section 2.7 and no reference to the Trademark. The labeling and packaging for the Generic Product shall be subject to the prior approval of Salix, which approval shall not be unreasonably withheld or delayed. Salix shall only be obligated to
supply to Watson Generic Product in the packaging configurations set forth in Exhibit D. Watson shall be solely responsible for the content of all labeling and packaging print copy and Watson shall ensure that all such labeling and packaging print
copy complies with all Applicable Laws. Any changes to the packaging and labeling of the Generic Product requested by Watson shall require the prior written consent of Salix, which approval shall not be unreasonably withheld or delayed. If Salix
consents to such changes, such changes shall be effected at Watson’s sole cost and expense. 
  

 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 

11 

 4.7. Supply Discussions. As soon as reasonably practicable after the Effective Date, the parties
shall engage in good faith discussions for a period of not less than ninety (90) days to attempt to agree on the terms and conditions on which Watson would Manufacture and supply to Salix Branded Product and Generic Product; it being
acknowledged and agreed by Watson and Salix that neither party shall have any obligation to enter into any such manufacturing and supply agreement and that either party may determine not to enter into such an agreement in its sole and absolute
discretion. 
 4.8. Salix Premises. Salix will permit Watson’s independent and qualified representatives acceptable to Salix,
which acceptance will not be unreasonably withheld, access, no more than once each calendar year, or more frequently in the event of a For Cause Incident, all at reasonable times and on reasonable notice, to Salix’s Manufacturing facilities for
Generic Product to conduct inspections of the premises where the Generic Product is being manufactured, tested and stored. All of Watson’s representatives will be obligated to execute a reasonable confidentiality agreement prior to commencing
any such inspection and at all times during any such inspection shall be accompanied by a representative of Salix. Watson will provide Salix with a written report of the results of any inspections of Salix’s Manufacturing facilities for Generic
Product by Watson’s independent and qualified representatives within thirty (30) days of any such inspection. If Salix disputes the findings of the inspection, such dispute will be resolved through the resolution procedures set forth in
the Quality Agreement. To the extent the Generic Product is Manufactured for Salix by a Third Party, Salix shall use Commercially Reasonable Efforts to obtain the consent of such Third Party to submit to and participate in such inspections as set
forth in this Section 4.8. For the avoidance of doubt, any and all observations, information and data resulting from or in connection with any such inspection shall be highly confidential information of Salix, shall not be disclosed by Watson
to any Person, and shall be used by Watson solely for purposes of ensuring compliance by Salix with its obligations hereunder. 
 ARTICLE
5. PRICE; COSTS 
 5.1. Purchase Price. The price payable by Watson (the “Purchase Price”) for all Generic Product
delivered hereunder shall be $[*] per 750 mg capsule. 
 5.2. Payment. Salix shall invoice Watson for all Generic
Product promptly after delivery thereof. Watson shall pay the applicable Purchase Price for each delivery of Generic Product within forty-five (45) days after the date of the applicable invoice. In the event that the terms of any invoice are
not consistent with or are in addition to the terms of this Agreement, the terms of this Agreement shall prevail. 
  

 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 

12 

 ARTICLE 6. PRODUCT WARRANTY AND LIMITATIONS 
 6.1. Warranty. Salix warrants that all Generic Product supplied by it hereunder, at the time of delivery thereof, (a) will comply with the
Specifications, (b) will have been Manufactured in material compliance with cGMP and all other Applicable Laws, (c) will not be adulterated or misbranded within the meaning of the Act, and (d) may be introduced into interstate
commerce pursuant to the Act. Salix further warrants and represents that, to its knowledge, the Manufacture, use, offer for sale, sale and importation of the Generic Product in the Territory in accordance with this Agreement does not infringe any
issued and enforceable patent of any Third Party. 
 6.2. Disclaimer of Other Warranties. EXCEPT AS EXPRESSLY SET FORTH IN THIS
AGREEMENT, THE PARTIES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE OR WARRANTY OF MERCHANTABILITY. 
 6.3. Noncompliant Product. 
 (a) In
the event that Watson determines that any Generic Product delivered to it hereunder does not comply with the warranty set forth in Section 6.1, Watson shall give Salix written notice of such noncompliance and the reasons therefor (including
sufficient samples for confirmatory testing, if applicable) (a) within thirty (30) days after delivery, in the case of noncompliance readily discoverable by a customary inspection of such Generic Product upon delivery thereof, or
(b) within fifteen (15) days after discovery, in the case of noncompliance not readily discoverable by a customary inspection of such Generic Product upon receipt thereof. Salix shall evaluate, or cause to be evaluated, such Generic
Product (including appropriate testing of the samples provided by Watson, if applicable) and notify Watson within fifteen (15) business days after receipt of Watson’s notice whether it has confirmed such noncompliance. If Salix notifies
Watson that it has not confirmed such noncompliance and Watson continues to believe such Generic Product is noncompliant, Salix and Watson promptly shall submit the dispute to an independent testing laboratory or other applicable expert of
recognized standing in the industry mutually acceptable to Salix and Watson. Each party shall cooperate with the laboratory or other expert in its evaluation. The findings of the laboratory or other expert shall be binding on the parties. The
expenses for such laboratory or other expert shall be borne by the party whose analysis was not substantiated by the findings of such laboratory or other expert. 
 (b) If, pursuant to Section 6.3(a), any Generic Product is determined not to comply with the warranty set forth in Section 6.1, then Salix promptly shall replace such noncompliant Generic Product with
compliant Generic Product, and any such noncompliant Generic Product that is in Watson’s control shall be destroyed pursuant to Salix’s reasonable instructions and at Salix’s expense. Salix may, if it so requests, be present at the
destruction of such Generic Product. Except as set forth in Sections 7.3 and 10.2, the remedies set forth in this Section 6.3(b) shall constitute Watson’s sole and exclusive remedy for any breach by Salix of the warranty set forth in
Section 6.1. 
  

 13 

 ARTICLE 7. QUALITY CONTROL 
 7.1. Quality and Safety Agreements. Prior to the Launch Date, the parties shall enter into a Quality Agreement relating to quality assurance
matters for the Generic Product and a Safety Agreement relating to adverse experience reporting and other safety matters for the Generic Product, in each case on customary and reasonable terms, and each party shall duly and punctually perform all of
its obligations under and pursuant to such Quality Agreement and Safety Agreement. 
 7.2. Information Requests. Salix shall have the
exclusive right to respond to all questions or requests for information about the Generic Product made by any medical professionals or any other Person to Watson that are beyond the scope of the labeling for the Generic Product. Watson promptly
shall communicate to Salix all such questions or requests. 
 7.3. Recalls. In the event Salix shall be required or shall voluntarily
decide to recall any Generic Product or take any other market withdrawal with respect to any Generic Product, then Watson shall fully cooperate with Salix and comply with Salix’s instructions in the carrying out of such recall and/or market
withdrawal. Salix shall be responsible for all recall and/or market withdrawal expenses except to the extent such recall and/or market withdrawal is initiated because of a defect in the Generic Product which is attributable to a breach by Watson of
its representations, warranties, covenants or agreements under this Agreement. In such event, Watson shall reimburse Salix for recall and/or market withdrawal expenses incurred by Salix or its Affiliates in connection therewith to the extent
attributable to such breach. Prior to determining whether to implement a recall or market action with respect to the Generic Product, Salix shall consult in good faith with Watson; provided that if the parties do not agree whether a recall and/or
market action should be implemented, the decision to initiate a recall and/or market action shall be made by Salix. Notwithstanding the foregoing, Watson shall not be restricted from taking any action which Watson believes in good faith after
consultation with its legal counsel is required by law or regulation. 
 7.4. Withdrawal. In the event Salix elects to withdraw the
NDA from the Territory, then Watson shall fully cooperate with Salix and comply with Salix’s instructions in the carrying out of such withdrawal if so instructed by Salix. Except as set forth in Section 11.9(g)(iv), all expenses incurred
by Watson or its Affiliates in connection with such withdrawal shall be borne by Salix. Watson acknowledges and agrees that Salix shall have the right to withdraw the NDA from the Territory at any time in its sole and absolute discretion.

 7.5. Noncompliance. If Salix discovers that any lot of Generic Product previously delivered to Watson by Salix under this Agreement
fails to comply with the warranty set forth in Section 6.1, Salix shall promptly notify Watson of such failure and the nature thereof in detail. Salix shall promptly investigate all such failures and provide the findings of such investigation
to Watson. Salix shall consult with Watson in an effort to arrive at an acceptable procedure for taking appropriate action in response to such failure. 
 7.6. Change to Specifications. Salix in its sole discretion shall have the right to change the Specifications and the process of Manufacturing Generic Product from time to time; provided that Salix shall give
Watson reasonable (under the circumstances) advance notice of 

  

 14 

 
any such change. Salix shall not be required to make any change to the Specifications or the process of Manufacturing Generic Product requested by Watson.
The costs associated with all changes to the Specifications or the process of Manufacturing Generic Product shall be borne by Salix unless such change was requested by Watson and approved by Salix, in which event Watson shall bear all of such costs.

 7.7. Returns. In the event that Salix receives any returned goods of Generic Product from a Third Party, Salix shall notify Watson
of such returned goods and destroy such returned goods at Watson’s sole expense. Watson shall not have the right to return any Generic Product to Salix, other than in accordance with Section 4.2(d) and Article 11. 
 7.8. Batch Records. Batch records, including information relating to the Manufacturing for each lot of finished Generic Product produced
hereunder, will be prepared in accordance with cGMP. Batch records and all other records relating to Manufacturing hereunder shall be retained by Salix for such period of time as is required under applicable rules and regulations of the FDA. In the
event (i) Salix receives a regulatory letter or comments from any federal agency in connection with its Manufacture of Generic Product or the facility(ies) where Generic Product is Manufactured requiring a response or action by Salix, or the
Third Party manufacturer, including, but not limited to, receipt of a Form 483 (Inspectional Observations) or a “Warning Letter,” or (ii) any batch of Generic Product purchased by Watson pursuant to this Agreement is the subject of a
recall or market withdrawal (each of (i) and (ii) a “For Cause Incident”), promptly following Watson’s prior written request therefor, Salix shall make available to Watson, at Salix’s premises during business hours, a
complete copy of an executed batch record for each SKU of Generic Product associated with such For Cause Incident. Additionally, Salix shall, upon Watson’s written request in connection with any audit under Section 4.8, and to the extent
applicable, make available for review by Watson during the course of such audit, updates to the process validation report and equipment cleaning validation for Generic Product. Any representative of Watson shall be accompanied by a representative of
Salix at all times during any such review. All records made available to Watson hereunder shall be considered highly confidential materials of Salix, shall not be disclosed by Watson to any person, and shall be used by Watson solely for purposes of
ensuring compliance by Salix with its obligations hereunder. 
 ARTICLE 8. REGULATORY INTERACTIONS 
 8.1. Control of NDA. Salix shall have the exclusive responsibility for maintenance of the NDA and the conduct of all regulatory actions with
respect to, and communications and filings with and submissions to, the FDA with respect to the NDA and the marketing, distribution and sale of the Generic Product under this Agreement, including making all filings with the FDA required for any
Specification or Manufacturing change, as well as reporting of adverse events. Salix, at its expense, shall use Commercially Reasonable Efforts to make such filings with the FDA as are necessary for Salix to perform its obligations under this
Agreement. 
 8.2. Cooperation. Each party, at the expense of the other party, shall provide the other party with all reasonable
assistance and take all actions reasonably necessary to enable such other party to comply with all Applicable Laws in connection with such other party’s activities under this Agreement. 
  

 15 

 ARTICLE 9. REPRESENTATIONS AND WARRANTIES 
 9.1. Warranties. Each party represents, warrants and covenants to the other that: 
 (a) it, its Affiliates, and its and their employees have not been, and during the Term will not be, debarred under Section 306 of the Act or excluded
from participation in any Federal or state healthcare program or Federal or state contract; 
 (b) it has no and will have no conflict of
interest in performing its obligations under this Agreement; 
 (c) it is not and will not be prohibited from performing under this Agreement
as a result of any contract, agreement or other arrangement, whether oral or written; and 
 (d) it has not been convicted of or pled nolo
contendere to any felony or to any Federal or state legal violation relating to prescription drug products. 
 9.2. Warranties. Salix
further represents, warrants and covenants to Watson that: 
 (a) Salix will perform all stability and other testing sufficient to maintain
the Generic Product in conformity with the NDA. 
 (b) Salix will not sell the Generic Product to any Third Party outside of the Territory if
Salix knows, or should have known, that such Third Party intends to resell the Generic Product inside of the Territory. 
 ARTICLE 10.
INDEMNITY 
 10.1. Watson Indemnity. Watson shall defend, indemnify and hold harmless Salix, its Affiliates and their respective
directors, officers, shareholders, employees and agents, and their respective successors and permitted assigns (“Salix Indemnitees”) from any and all claims, actions, causes of action, liabilities, losses, costs, damages or expenses,
including reasonable attorneys’ fees (“Losses”), which directly or indirectly arise out of or relate to (a) a breach or failure to perform by Watson of any warranty, representation, covenant or agreement made by Watson in this
Agreement, (b) the negligence, recklessness or willful misconduct of Watson in the performance of its obligations under this Agreement, or (c) any Third Party allegations, claims, investigations or demands relating to Watson’s sale of
Generic Product using Watson trade dress, in each case except for those Losses for which Salix has an obligation to indemnify the Watson Indemnitees pursuant to Section 10.2, as to which Losses each party shall indemnify the other to the extent
of its respective liability. 
 10.2. Salix Indemnity. Salix shall defend, indemnify and hold harmless Watson, its Affiliates and
their respective directors, officers, shareholders, employees and agents, and their respective successors and permitted assigns (the “Watson Indemnitees”), from any and all Losses which directly or indirectly arise out of or relate to
(a) a breach or failure to perform by Salix of any warranty, representation, covenant or agreement made by Salix in this Agreement, (b) the negligence, recklessness or willful misconduct of Salix in the performance of its obligations under
this Agreement, (c) any death or personal injury arising from the use of the Generic 

  

 16 

 
Product, (d) any Third Party allegation that the marketing and sale by Watson of the Generic Product in the Territory in accordance with the terms of
this Agreement infringes or violates any patent, trade secret, copyright, trademark or other intellectual property rights of any Third Party, or (e) any Third Party allegations, claims, investigations or demands relating to Watson’s sale
of Generic Product bearing Salix trade dress, including, but not limited to any Third Party allegations, claims, investigations or demands arising from the packaging of capsules bearing a capsule image that is the same as the capsule image of the
Branded Product in Watson trade dress for subsequent sale as Generic Product in each case except for those Losses for which Watson has an obligation to indemnify the Salix Indemnitees pursuant to Section 10.1, as to which Losses each party
shall indemnify the other to the extent of its respective liability. 
 10.3. Procedures. The indemnified party shall give the
indemnifying party (a) prompt written notice of any claims made for which the indemnified party knows or reasonably should know the indemnifying party reasonably may be liable under the foregoing indemnification and (b) the opportunity to
defend, negotiate, and settle such claims. The indemnified party shall provide the indemnifying party with all information in its possession, all authority and all assistance necessary to enable the indemnifying party to carry on the defense of such
suit; provided, however, that the indemnified party reserves the right to retain its own counsel to defend itself in, but not control the defense of, such suit, at its own expense, unless (i) the interests of the indemnified party and the
indemnifying party in the suit conflict in such a manner and to such extent as to require, consistent with applicable standards of professional responsibility, the retention of separate counsel for the indemnified party, in which case, the
indemnifying party will pay for one separate counsel chosen by the indemnified party or (ii) the indemnifying party shall not have employed attorneys reasonably satisfactory to the indemnified party to defend any action within a reasonable time
after notice of commencement of such action. Neither party shall be responsible to or bound by any settlement made by the other party without its prior written consent, which shall not be unreasonably withheld or delayed. 
 10.4. Limitation of Liability. EXCEPT FOR THE PARTIES’ INDEMNIFICATION OBLIGATIONS FOR THIRD PARTY CLAIMS UNDER SECTIONS 10.1 AND 10.2, IN NO
EVENT WILL EITHER PARTY OR ITS AFFILIATES BE LIABLE FOR ANY PUNITIVE, SPECIAL, INDIRECT, CONSEQUENTIAL OR INCIDENTAL DAMAGES OR LOSSES OF ANY KIND, NATURE OR DESCRIPTION WHATSOEVER, INCLUDING BUT NOT LIMITED TO LOST PROFITS, REGARDLESS OF WHETHER
ARISING FROM BREACH OF CONTRACT, WARRANTY, TORT, STRICT LIABILITY OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH LOSS OR DAMAGE OR IF SUCH LOSS OR DAMAGE COULD HAVE BEEN REASONABLY FORESEEN. 
 10.5. Insurance. Each party shall maintain comprehensive general liability insurance, including product liability insurance against claims related
to the Manufacture and commercialization of the Generic Product under this Agreement, in amounts of not less than $[*] for each claim and $[*] in the aggregate, both during the Term and thereafter for so long as it
customarily maintains insurance for itself for similar products and activities. 
 10.6. Nothing in this Article 10 will act to negate any
obligation under common law of either Party to mitigate damages with respect to any Losses for which such Party is seeking indemnification from the other Party hereunder. 
  

 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 
 17 

 ARTICLE 11. TERM AND TERMINATION 
 11.1. Term. Unless earlier terminated in accordance with the terms hereof, the term of this Agreement (the “Term”) shall commence on the
Effective Date and shall continue until the fifth (5th) anniversary of the Effective Date, and shall thereafter automatically renew for additional one-year periods unless either party gives the other party written notice at least six
(6) months prior to the expiration of the initial five (5)-year period or the applicable renewal period. 
 11.2. Termination by
Salix. This Agreement may be terminated by Salix: 
 (a) If Watson shall be in breach of any material obligation hereunder and has not
cured such breach within [*] ([*]) days after receipt of a notice from Salix requesting the cure of such breach. Such termination shall be effective upon failure of Watson to cure such breach within such period; or

 (b) Upon the filing or institution of any bankruptcy, reorganization, liquidation or receivership proceedings by Watson, or upon the
failure by Watson for more than ninety (90) days to discharge any such actions against it. Such termination shall be effective upon receipt of notice from Salix; or 
 (c) If a Force Majeure event affecting the performance of Watson specified in Section 13.2 shall continue for more than [*] ([*]) consecutive days. Such termination shall be effective
upon receipt of notice from Salix; or 
 (d) Upon written notice given by Salix to Watson at least thirty (30) days prior to the end of
any Calendar Quarter, if Salix, in its sole and absolute discretion, determines that this Agreement has become commercially unviable as the result of [*]. Such termination shall be effective at midnight of the last day of the Calendar
Quarter immediately following the Calendar Quarter in which notice of termination is given by Salix; or 
 (e) In the event that at any time
during the Term Salix obtains the legal right, through the enforcement of Salix’s intellectual property or other rights, to prohibit the marketing and sale of Equivalent Products in the Territory, Salix may terminate this Agreement upon thirty
(30) days’ prior notice to Watson; or 
 (f) In the event that at any time during the Term Salix ceases distribution of the Branded
Product, Salix, after consultation with Watson, may terminate this Agreement upon thirty (30) days’ prior notice to Watson. 
 11.3. Termination by Watson. This Agreement may be terminated by Watson: 
 (a) If Salix shall be in breach of any material
obligation hereunder (other than failure to deliver Generic Product) and has not cured such breach within [*] ([*]) days after receipt of a notice from Watson requesting the cure of such breach. Such termination shall be
effective upon failure of Salix to cure such breach within such period; or 
 (b) Upon the filing or institution of any bankruptcy,
reorganization, liquidation or receivership proceedings by Salix, or upon the failure by Salix for more than ninety (90) days to discharge any such actions against it. Such termination shall be effective upon receipt of notice from Watson; or

  

 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 

18 

 (c) If a Force Majeure event affecting the performance of Salix specified in Section 13.2 shall
continue for more than [*] ([*]) consecutive days. Such termination shall be effective upon receipt of notice from Watson; or 
 (d) If for any reason (other than a Force Majeure event) Generic Product is not supplied by the delivery date set forth in a Firm Order submitted in accordance with Section 4.2 and Salix’s failure to supply
remains uncured for a period of [*] ([*]) days beyond the applicable delivery date(s) specified in such Firm Order, Watson shall have the right to terminate this Agreement with 30 days’ prior written notice of such
termination to Salix; or 
 (e) If for any reason [*], Watson will have the right to terminate this Agreement with 30 days’ prior
written notice of such termination to Salix. 
 11.4. Change of Control. 
 (a) No later than ten (10) days following the earlier of (a) the effective date of a Change of Control and (b) the public announcement by
or on behalf of Watson or Parent of the entry by Watson or Parent into a definitive agreement providing for a Change of Control, Watson shall provide written notice to Salix informing Salix of such transaction. If any Person or group that controls
(or would control) Watson and/or Parent (or assumes Watson’s rights and obligations hereunder) as a result of such Change of Control is not reasonably acceptable to Salix, Salix may terminate this Agreement (i) in the case of notice
provided in accordance with subsection (a) above, effective immediately, upon written notice to Watson and (ii) in the case of notice provided in accordance with subsection (b) above, upon ninety (90) days prior written notice,
provided that, if the effective date of the Change of Control occurs prior to the end of such ninety (90) day period, the effective date of such termination shall be the effective date of the Change of Control. 
 (b) If during the Term Watson or an Affiliate enters into an agreement (an “Acquisition Agreement”) pursuant to which Watson becomes an
Affiliate of a Person that (i) develops, manufactures, markets or sells an Equivalent Product and (ii) prior to the date of the Acquisition Agreement was a Third Party, and provided that the primary purpose of such Acquisition
Agreement was for something other than acquiring rights to the Equivalent Product, (A) Watson will immediately notify Salix of the entry into such Acquisition Agreement (the “Acquisition Notice”), (B) [*], (C) Watson shall
have the right to terminate this Agreement upon one-hundred-eighty (180) days’ prior written notice of such termination to Salix, but such termination shall only be effective upon completion of the transactions contemplated by such
Acquisition Agreement (which in no event shall relieve Watson of any obligation under Section 2.12 prior to the effective date of such termination), and (D) Salix shall have the right to terminate this Agreement, effective immediately,
upon written notice to Watson. In addition to its obligations under Section 11.9(j) or 11(k), as the case may be, Watson shall pay to Salix, not later than forty-five (45) days after the end of each month during the period commencing on
the date of delivery of the Acquisition Notice and ending on the last day of the month in which the effective date of termination occurs, an amount (if any) equal to the positive difference between (1) [*]% of the Average Monthly
Profits, less (2) [*]% of the actual Profits for such month. 
  

 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 

19 

 11.5. Withdrawal of NDA. In the event Salix elects to withdraw the NDA from the Territory, this
Agreement automatically shall terminate upon such withdrawal. 
 11.6. Agency Action. In the event that any governmental entity
determines that this Agreement violates any Applicable Law, either Salix or Watson may terminate this Agreement immediately upon written notice to the other party. 
 11.7. Statutory Rights. Watson acknowledges that it is cognizant of certain state statutes that impose on a wholesaler, distributor or importer specific duties and obligations with regard to the termination of
a distribution agreement. Notwithstanding the rights conferred under those statutes to a distributor, Watson hereby waives its rights thereunder with respect to a valid termination by Salix pursuant to a termination right under this Agreement and in
consideration of its appointment hereunder covenants not to sue Salix in the event of the termination of this Agreement by Salix pursuant to the terms hereof, except for the purpose of enforcing Watson’s express rights under this Agreement.

 11.8. [*]. 
 11.9. Effect of Expiration or Termination. 
 (a) Upon expiration of the Term of this Agreement, Watson shall be permitted to
sell off any inventory of Generic Product in its possession as of the date of expiration. 
 (b) Upon termination of this Agreement by Salix
pursuant to Section 11.2(a) or by Watson pursuant to Section 11.8:  
  

	 	(i)	Watson immediately shall cease all sales, marketing and distribution of the Generic Product and Watson shall immediately destroy any inventory of Generic Product under its control,
at its expense, and shall either, at Salix’s option, (A) allow a Salix representative to be present during such destruction or (B) provide a certificate of such destruction. 

  

	 	(ii)	All then outstanding Firm Orders automatically shall be cancelled. 

  

	 	(iii)	Watson promptly shall reimburse Salix for all actual and reasonable costs incurred by Salix to complete activities associated with the termination of this Agreement, including,
without limitation (A) the costs of all Materials purchased by Salix up to the effective date of termination which cannot be diverted to Salix’s other uses and which are non-refundable and (B) the Purchase Price for any finished
Generic Product and the cost of any work in process which cannot be diverted to Salix’s other uses held by Salix as of the effective date of termination and Manufactured by Salix in accordance with Firm Orders then outstanding.

  

 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 

20 

	 	(iv)	To the extent any amount reimbursable by Salix pursuant to Section 3.1(b) has not been reimbursed by Salix or credited against Profits payable by Watson as of the date of
termination, Salix shall reimburse such amount to Watson within sixty (60) days after the date of termination. 

 (c) Upon
termination of this Agreement by Salix pursuant to Section 11.2(b) or (c): 
  

	 	(i)	Watson shall be permitted to sell off any inventory of Generic Product in its possession as of the date of termination. 

  

	 	(ii)	All then outstanding Firm Orders automatically shall be cancelled. 

  

	 	(iii)	Watson promptly shall reimburse Salix for all actual and reasonable costs incurred by Salix to complete activities associated with the termination of this Agreement, including,
without limitation (A) the costs of all Materials purchased by Salix up to the effective date of termination which cannot be diverted to Salix’s other uses and which are non-refundable and (B) the Purchase Price for any finished
Generic Product and the cost of any work in process which cannot be diverted to Salix’s other uses held by Salix as of the effective date of termination and Manufactured by Salix in accordance with Firm Orders then outstanding.

 (d) Upon termination of this Agreement by Salix pursuant to Section 11.2(d): 
  

	 	(i)	All then outstanding Firm Orders automatically shall be cancelled. 

  

	 	(ii)	Watson immediately shall cease all sales, marketing and distribution of the Generic Product and Salix promptly shall repurchase all saleable inventory of the Generic Product held by
Watson as of the date of termination at the Purchase Price paid for such Generic Product, and Watson shall deliver such Generic Product to Salix at Salix’s expense. 

 (e) Upon termination of this Agreement by Watson pursuant to Section 11.3 or by Salix pursuant to Section 11.8: 
  

	 	(i)	All then outstanding Firm Orders automatically shall be cancelled. 

  

	 	(ii)	Watson shall be permitted to sell off any inventory of Generic Product in its possession as of the date of termination. 

  

 21 

	 	(iii)	To the extent any amount reimbursable by Salix pursuant to Section 3.1(b) has not been reimbursed by Salix or credited against Profits payable by Watson as of the date of
termination, Salix shall reimburse such amount to Watson within sixty (60) days after the date of termination. 

 (f) Upon
termination of this Agreement by Salix pursuant to Section 11.2(f) or 11.4(a): 
  

	 	(i)	All then outstanding Firm Orders automatically shall be cancelled; provided that, if on the date of termination Watson holds less than [*] months’ of
inventory of the Generic Product (determined based on the average monthly amount of Generic Product sold by Watson and its Affiliates during the [*] full month-period prior to the date of termination), then, at Watson’s option,
Salix will fulfill, in accordance with the terms of this Agreement and such Firm Orders, that portion of any outstanding Firm Orders necessary to supply Watson a quantity of Generic Product equal to the difference between [*]
months’ inventory and the quantity of Generic Product actually held by Watson on the date of termination. 

  

	 	(ii)	Watson shall be permitted a sell-off period of [*] days to sell off any inventory of Generic Product in its possession as of the date of termination. Watson
immediately shall cease all sales, marketing and distribution of the Generic Product at the end of such selloff period and Salix promptly shall repurchase all saleable inventory of the Generic Product held by Watson as of the end of such selloff
period at the Purchase Price paid by Watson for such Generic Product, and Watson shall deliver such Generic Product to Salix at Salix’s expense. 

 (g) Upon termination of this Agreement by Salix pursuant to Section 11.5: 
  

	 	(i)	All then outstanding Firm Orders automatically shall be cancelled. 

  

	 	(ii)	Watson immediately shall cease all sales, marketing and distribution of the Generic Product. 

  

	 	(iii)	Salix promptly shall repurchase (A) all saleable inventory of the Generic Product held by Watson as of the date of termination and (B) all Generic Product recovered by
Watson from customers in accordance with subsection (iv) below, in each case at the Purchase Price paid for such Generic Product, and Watson shall deliver such Generic Product to Salix at Salix’s expense. 

  

	 	(iv)	Under the direction of Salix, Watson shall, at Salix’s expense (excluding any refunds to customers, which shall be paid by 

  

 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 
 22 

	 	 
Watson and taken into account in the calculation of Net Sales), use its best efforts to recover all Generic Product which has been delivered to Watson but is
no longer within Watson’s control, other than such Generic Product that has been consumed; provided that if any refunds paid to a customer by Watson under this Section 11.8(g)(iv) would reduce the Profits for any period with respect to
which a payment of Profits had already been made by Watson to Salix pursuant to Section 3.2, Salix promptly shall pay to Watson the amount necessary such that the proper allocation of Profits for such period pursuant to Section 3.1, taking
into account such refunds, shall be achieved. 

 (h) Upon termination of this Agreement by either party pursuant to
Section 11.6: 
  

	 	(i)	All then outstanding Firm Orders automatically shall be cancelled. 

  

	 	(ii)	Watson immediately shall cease all sales, marketing and distribution of the Generic Product and Watson shall immediately destroy any inventory of Generic Product under its control
and shall either, at Salix’s option, (i) allow a Salix representative to be present during such destruction or (ii) provide a certificate of such destruction. 

  

	 	(iii)	Salix shall bear [*]% and Watson shall bear [*]% of all actual and reasonable costs incurred by the parties to complete activities associated with the
termination of this Agreement, including, without limitation, (A) the costs of all Materials purchased by Salix up to the effective date of termination which cannot be diverted to Salix’s other uses and which are non-refundable,
(B) the cost of any Generic Product and any work in process which cannot be diverted to Salix’s other uses held by Salix as of the effective date of termination and Manufactured by Salix in accordance with Firm Orders then outstanding, and
(C) the Purchase Price paid by Watson for any Generic Product held by Watson as of the date of termination. Each party shall use Commercially Reasonable Efforts to minimize the costs it incurs to complete activities associated with the
termination of this Agreement. 

  

	 	(iv)	Each party acknowledges and agrees that the other party shall have no liability of any kind to such first party, other than as provided in this Section 11.9(h), for termination
of this Agreement under Section 11.6. 

  

 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 

23 

 (i) Upon termination of this Agreement by Salix pursuant to Section 11.2(e): 
  

	 	(i)	All then outstanding Firm Orders automatically shall be cancelled. 

  

	 	(ii)	Watson immediately shall cease all sales, marketing and distribution of the Generic Product and Salix promptly shall repurchase all saleable inventory of the Generic Product held by
Watson as of the termination date at the Purchase Price paid by Watson for such Generic Product, and Watson shall deliver such Generic Product to Salix at Salix’s expense. 

  

	 	(iii)	Salix shall reimburse Watson for any reasonable and customary supplier penalties that are incurred by Watson for cancellation of customer supply contracts that exist as of the date
of the notice for such termination. 

 (j) Upon termination of this Agreement by Watson pursuant to Section 11.4(b):

  

	 	(i)	Watson immediately shall cease all sales, marketing and distribution of the Generic Product and Watson shall immediately destroy any inventory of Generic Product under its control,
at its expense, and shall either, at Salix’s option, (A) allow a Salix representative to be present during such destruction or (B) provide a certificate of such destruction. 

  

	 	(ii)	All then outstanding Firm Orders automatically shall be cancelled. 

  

	 	(iii)	For a period of twelve (12) months from the effective date of such termination, Watson shall make monthly payments to Salix, not later than forty-five (45) days after the
end of each month during such twelve (12) month period, each of which payments shall be equal to [*]% of the Average Monthly Profits. 

 (k) Upon termination of this Agreement by Salix pursuant to Section 11.4(b): 
  

	 	(i)	Watson immediately shall cease all sales, marketing and distribution of the Generic Product and Salix promptly shall repurchase all saleable inventory of the Generic Product held by
Watson as of the termination date at the Purchase Price paid by Watson for such Generic Product, and Watson shall deliver such Generic Product to Salix at Salix’s expense. 

  

	 	(ii)	All then outstanding Firm Orders automatically shall be cancelled. 

  

	 	(iii)	For a period of twelve (12) months from the effective date of such termination, Watson shall make monthly payments to Salix, not later than forty-five (45) days after the
end of each month during such twelve (12) month period, each of which payments shall be equal to [*]% of the Average Monthly Profits. 

  

 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 

24 

 11.10. Sales During Selloff Period. During any selloff period after the expiration or termination
of this Agreement permitted under Section 11.9, Watson shall store, handle, market, sell and distribute the Generic Product pursuant to all terms and conditions of this Agreement in effect prior to such expiration or termination. 
 11.11. Reconciliation. For a period of two (2) years from the date of any termination or expiration of this Agreement, Watson shall,
initially no later than sixty (60) days after the six-month anniversary of the end of the Calendar Quarter within which the Agreement expired or was terminated, and quarterly thereafter, prepare and deliver to Salix a reasonably detailed report
(each, a “Profits Report”), of the cumulative Profits from the Effective Date through the end of the period covered by the Profits Report which reconciles (i) previously estimated amounts of Profits with (ii) actual experience
for the period covered by the Profits Report (the difference, if any, the “Reconciled Amount”). If the Profits Report shows a positive adjustment to Profits, Watson shall pay to Salix [*] percent ([*]%) of the
Reconciled Amount within fifteen (15) days of Salix’s receipt of the Profits Report. If the Profits Report shows a negative adjustment to Profits, Salix shall pay to Watson [*] percent ([*]%) of the Reconciled
Amount within fifteen (15) days of Salix’s receipt of the Profits Report. 
 11.12. Accrued Rights. The expiration or
termination of this Agreement shall not affect the rights and obligations of the parties arising prior to such expiration or termination. 
 ARTICLE 12. CONFIDENTIAL INFORMATION 
 12.1. Confidential Information. 
 (a) For purposes of this Agreement, “Confidential Information” means any and all information or material, whether oral, visual, in writing or in
any other form, that, at any time before or after the date hereof, has been or is provided, communicated or otherwise made known to the Receiving Party by or on behalf of the Disclosing Party pursuant to this Agreement or in connection with the
transactions contemplated hereby or any discussions or negotiations with respect thereto; any data, ideas, concepts or techniques contained therein; and any modifications thereof or derivations therefrom. 
 (b) Except to the extent expressly permitted by this Agreement and subject to the provisions of Sections 12.2 and 12.3, at all times during the Term and
for a period of seven (7) years following the expiration or termination thereof, the Receiving Party shall keep completely confidential and shall not publish or otherwise disclose or use, directly or indirectly, for any purpose, any
Confidential Information of the Disclosing Party, except to those of the Receiving Party’s employees, Affiliates or consultants who have a need to know such information (collectively, “Recipients”) to perform the Receiving
Party’s obligations hereunder (and who shall be advised of the Receiving Party’s obligations hereunder and who are bound by confidentiality obligations with respect to such Confidential Information no less onerous than those set forth in
this Agreement). The Receiving Party shall be jointly and severally liable for any breach by any of its Recipients of the restrictions set forth in this Agreement. 
  

 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 

25 

 12.2. Exceptions to Confidentiality. The Receiving Party’s obligations set forth in
this Agreement shall not extend to any Confidential Information of the Disclosing Party: 
 (a) that is or hereafter becomes part of the
public domain by public use, publication, general knowledge or the like through no wrongful act, fault or negligence on the part of a Receiving Party or its Recipients; 
 (b) that is received from a Third Party without restriction and without breach of any obligation of confidentiality between such Third Party and the Disclosing Party; 
 (c) that the Receiving Party can demonstrate by competent evidence was already in its possession without any limitation on use or disclosure prior to its
receipt from the Disclosing Party; 
 (d) that is generally made available by a Third Party or otherwise enters the public domain without
restriction on disclosure and through no fault of the Receiving Party in breach of this Agreement; or 
 (e) that the Receiving Party can
demonstrate by competent evidence was independently developed by the Receiving Party. 
 12.3. Permitted Disclosures. Each party and
its Recipients may disclose Confidential Information to the extent that such disclosure is: 
 (a) made in response to a valid order of a
court of competent jurisdiction or other Agency of a country or any political subdivision or regulatory body thereof of competent jurisdiction; provided, however, that the Receiving Party shall first have given notice to the Disclosing Party and
given the Disclosing Party a reasonable opportunity to quash such order or to obtain a protective order requiring that the Confidential Information or documents that are the subject of such order be held in confidence by such court or Regulatory
Authority or, if disclosed, be used only for the purposes for which the order was issued; and provided further that if a disclosure order is not quashed or a protective order is not obtained, the Confidential Information disclosed in response to
such court or governmental order shall be limited to that information which is legally required to be disclosed in such response to such court or governmental order; or 
 (b) otherwise required by applicable law, in the opinion of legal counsel to the Receiving Party as expressed in an opinion letter in form and substance reasonably satisfactory to the Disclosing Party, and the
Receiving Party shall exercise its commercially reasonable efforts to obtain a protective order or other reliable assurance that confidential treatment will be accorded to the Confidential Information so disclosed. 
 12.4. Notification. The Receiving Party shall notify the Disclosing Party immediately, and cooperate with the Disclosing Party as the Disclosing
Party may reasonably request, upon the Receiving Party’s discovery of any loss or compromise of the Disclosing Party’s Confidential Information. 
  

 26 

 12.5. Use of Name and Disclosure of Terms. No press release, public announcement, confirmation or
other communication to the public or Third Parties regarding the terms of this Agreement or related matters shall be made by either party without the prior written consent of the other party with respect to the form, content and timing of such press
release, public announcement, confirmation or other communication to the public or Third Parties, except that either party may confirm the existence, but not the terms, of this Agreement in response to press inquiries and in trade advertisements and
customer communications. Neither party shall mention or otherwise use the name, insignia, symbol, trademark, trade name or logotype of the other party or its Affiliates in any manner without the prior written consent of the other party in each
instance. The restrictions imposed by this Section 12.5 shall not prohibit either party from making any disclosure identifying the other party that is required by applicable law, rule or regulation or the requirements of a national securities
exchange or another similar regulatory body, provided that any such disclosure shall be governed by this Article 12 and that the other party is given a reasonable opportunity to review and comment on any such press release or public communication in
advance thereof. 
 ARTICLE 13. MISCELLANEOUS 
 13.1. Governing Law. 
 (a) The interpretation and construction of this Agreement shall be governed by
the laws of the State of New York, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. 
 (b) Each party further agrees that service of any process, summons, notice or document by registered mail to its address set forth in Section 13.5
shall be effective service of process for any action, suit or proceeding brought against it under this Agreement in any such court. 
 13.2.
Force Majeure. No liability shall result from delay in performance or non-performance, in whole or in part, by either of the parties to the extent that such delay or non-performance is caused by an event of Force Majeure. “Force
Majeure” means an event that is beyond a non-performing party’s reasonable control, including an act of God, act of the other party, strike, lock-out or other industrial/labor dispute, war, acts of war (whether war to be declared or not)
riot, civil commotion, terrorist act, malicious damage, epidemic, quarantine, fire, flood, storm, natural disaster or compliance with any law or governmental order, rule, regulation or direction, whether or not it is later held to be invalid. The
Force Majeure Party shall within thirty (30) days of the occurrence of the Force Majeure event give written notice to the other party stating the nature of the Force Majeure event, its anticipated duration and any action being taken to avoid or
minimize its effect. Any suspension of performance shall be of no greater scope and of no longer duration than is reasonably required. 
  

 27 

 13.3. Waiver and Non-Exclusion of Remedies. A party’s failure to enforce, at any time
or for any period of time, any provision of this Agreement, or to exercise any right or remedy shall not constitute a waiver of that provision, right or remedy or prevent such party from enforcing any or all provisions of this Agreement and
exercising any rights or remedies. To be effective any waiver must be in writing. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by law or otherwise available except as expressly set
forth herein. 
 13.4. Equitable Relief. The Parties acknowledge and agree that the restrictions set forth in Sections 2.4 and
2.12 and Article 12 are reasonable and necessary to protect the legitimate interests of the parties and that neither party would have entered into this Agreement in the absence of such restrictions, and that any breach or threatened breach of any
provision of Sections 2.4 or 2.12 or Article 12 will result in irreparable injury to the other party for which there will be no adequate remedy at law. In the event of a breach or threatened breach of any provision of Sections 2.4 or 2.12 or Article
12 by a party, the other party shall be authorized and entitled to obtain from any court of competent jurisdiction injunctive relief, whether preliminary or permanent, specific performance and an equitable accounting of all earnings, profits and
other benefits arising from such breach, which rights shall be cumulative and in addition to any other rights or remedies to which such party may be entitled in law or equity. The breaching party agrees to waive any requirement that the
non-breaching party (a) post a bond or other security as a condition for obtaining any such relief and (b) show irreparable harm, balancing of harms, consideration of the public interest or inadequacy of monetary damages as a remedy.
Nothing in this Section 13.4 is intended, or shall be construed, to limit the parties’ rights to equitable relief or any other remedy for a breach of any provision of this Agreement. 
 13.5. Notices. 
 (a) Any notice,
request, demand, waiver, consent, approval or other communication permitted or required under this Agreement shall be in writing, shall refer specifically to this Agreement and shall be deemed given only if delivered by hand or sent by facsimile
transmission (with transmission confirmed) or by nationally recognized overnight delivery service that maintains records of delivery, addressed to the parties at their respective addresses specified in Section 13.5(b) or to such other address
as the party to whom notice is to be given may have provided to the other party in accordance with this Section 13.5(a). Such notice shall be deemed to have been given as of the date delivered by hand or transmitted by facsimile (with
transmission confirmed) or on the second business day (at the place of delivery) after deposit with an internationally recognized overnight delivery service. Any notice delivered by facsimile shall be confirmed by a hard copy delivered as soon as
practicable thereafter. This Section is not intended to govern the day-to-day business communications necessary between the Parties in performing their obligations under the terms of this Agreement. 
 (b) Addresses for Notice. 
  

									
	For :	 		  	Salix Pharmaceuticals, Inc.	  		  	
					
	Address:	 		  	1700 Perimeter Park Drive	  		  	

  

 28 

									
				
		 		  	Morrisville, North Carolina 27560	  	
					
	Facsimile:	 		  	919-862-1095	  		  	
					
	Attention:	 		  	General Counsel	  		  	
					
	For:	 		  	Watson Pharmaceuticals, Inc.	  		  	
					
	Address:	 		  	311 Bonnie Circle	  		  	
					
		 		  	Corona, California 92880	  		  	
					
	Facsimile:	 		  	951-493-5821	  		  	
					
	Attention:	 		  	President – U.S. Generics	  		  	

 13.6. Entire Agreement. This Agreement and the Quality Agreement constitute the entire
agreement between the parties with respect to the subject matter hereof and thereof. This Agreement supersedes all prior agreements and understandings, whether written or oral, with respect to the subject matter of the Agreement. Each party confirms
that it is not relying on any representations, warranties or covenants of the other party except as specifically set out in this Agreement. Nothing in this Agreement is intended to limit or exclude any liability for fraud. All Exhibits referred to
in this Agreement are intended to be and are hereby specifically incorporated into and made a part of this Agreement. In the event of any inconsistency between any such Exhibit and this Agreement, the terms of this Agreement shall govern. In the
event of any inconsistency between the Quality Agreement and this Agreement, the terms of the Quality Agreement shall govern. 
 13.7.
Amendment. No amendment, modification, release or discharge of this Agreement shall be binding upon the parties unless in writing and signed by authorized representatives of both parties. 
 13.8. Assignment. Neither party shall sell, transfer, assign, delegate, pledge or otherwise dispose of its rights or delegate its
obligations under this Agreement, whether by operation of law or otherwise, in whole or in part without the prior written consent of the other party, except that (i) Salix shall always have the right, without such consent, to assign its rights
and delegate its obligations under this Agreement to any purchaser of or successor in interest to the business to which this Agreement relates and (ii) either party may assign its rights and obligations hereunder to any of its Affiliates,
without the consent of the other party, provided that the assigning party shall remain primarily liable for all its obligations and agreements set forth herein. All validly assigned rights of a party shall inure to the benefit of and be
enforceable by, and all validly delegated obligations of such party shall be binding on and be enforceable against, the permitted successors and assigns of such party. Any attempted assignment or delegation in violation of this Section shall be
void. 
  

 29 

 13.9. No Benefit to Others. The provisions of this Agreement are for the sole benefit of the
parties and their successors and permitted assigns, and they shall not be construed as conferring any rights in any other persons except as otherwise expressly provided in Article 10 of this Agreement. 
 13.10. Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original and all of which
taken together shall be deemed to constitute one and the same instrument. An executed signature page of this Agreement delivered by facsimile transmission shall be as effective as an original executed signature page. 
 13.11. Severability. To the fullest extent permitted by applicable law, the parties waive any provision of law that would render any provision in
this Agreement invalid, illegal or unenforceable in any respect. If any provision of this Agreement is held to be invalid, illegal or unenforceable, in any respect, then such provision will be given no effect by the parties and shall not form part
of this Agreement. Subject to Section 11.6, to the fullest extent permitted by Applicable Law and if the rights or obligations of any party will not be materially and adversely affected, all other provisions of this Agreement shall remain in
full force and effect and the parties will use their best efforts to negotiate a provision in replacement of the provision held invalid, illegal or unenforceable that is consistent with applicable law and achieves, as nearly as possible, the
original intention of the parties. 
 13.12. Further Assurance. Each party shall perform all further acts and things and execute and
deliver such further documents as may be necessary or as the other party may reasonably require to implement or give effect to this Agreement. 
 13.13. Relationship of the Parties. The status of a party under this Agreement shall be that of an independent contractor. Nothing contained in this Agreement shall be construed as creating a partnership, joint venture or agency
relationship between the parties or, except as otherwise expressly provided in this Agreement, as granting either party the authority to bind or contract any obligation in the name of or on the account of the other party or to make any statements,
representations, warranties or commitments on behalf of the other party, except upon the prior written consent of the other party to do so, such consent not to be unreasonably withheld or delayed. All persons employed by a party shall be employees
of such party and not of the other party and all costs and obligations incurred by reason of any such employment shall be for the account and expense of such party. 
 13.14. Payments. 
 (a) Form. All payments due hereunder shall be made by wire transfer to an
account designated by the receiving party in writing from time to time. 
 (b) Taxes and Withholding. 
  

	 	(i)	All payments made by one party to the other under this Agreement shall be made without any deduction or withholding for, or on account of, any tax. 

  

 30 

	 	(ii)	Any and all taxes (excluding income taxes based upon Salix’s income) relating to the supply of Generic Product to Watson under this Agreement, including, without limitation,
sales taxes required to be paid by any federal, state or local authority shall be borne by Watson. Official receipts indicating proof of payment of any such taxes shall be secured and made available to Salix upon request as evidence of payment.

 (c) Currency. All amounts payable by a party hereunder shall be paid in U.S. dollars. 
 (d) Interest on Late Payments. If any payment under this Agreement is not made within two (2) business days when due, interest shall accrue
on such past due amount from the date such amount was due until the date payment is actually made at a rate equal to the lesser of (a) 1.0% per month, compounded monthly, and (b) the maximum rate permitted by law. Time for any
payments hereunder shall be of the essence. 
 13.15. Headings. The headings of the Articles, Sections and subsections of this
Agreement are inserted for convenience only and shall not be deemed to constitute a part of this Agreement or affect the construction hereof. 
 13.16. Survival. The provisions of Sections 2.6, 2.8, 3.2, 3.3, 7.1, 7.3, 7.7, 11.7, 11.9, 11.10, 11.11, and 11.12 and Articles 1, 9, 10, 12 and 13 shall survive the expiration or termination of this Agreement for any reason.

 [The remainder of this page has been intentionally left blank.] 
  

 31 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the Effective Date. 
  

							
	SALIX PHARMACEUTICALS, INC.	 	WATSON PHARMA, INC.
				
	By:	 	 /s/ Carolyn J. Logan
	 	By:	 	 /s/ Andrew S. Boyer

	Name:	 	Carolyn J. Logan	 	Name:	 	Andrew S. Boyer
	Title:	 	President and CEO	 	Title:	 	Sr. VP Sales and Marketing

 PARENT GUARANTY 
 Watson Pharmaceuticals, Inc., a Nevada corporation, hereby guaranties the performance by Watson Pharma, Inc. of each and every covenant, agreement and obligation set forth in the Supply and Distribution Agreement to
which this guaranty is attached, when and as due in accordance with the terms of such Supply and Distribution Agreement. 
  

			
	WATSON PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Allen Chao

	Name:	 	Allen Chao
	Title:	 	Chairman and CEO

  

 32 

 EXHIBIT A 
 SPECIFICATIONS, TESTING AND IMAGE 
 [*] 
  

 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 

A-1 

 EXHIBIT B 
 DESCRIPTION OF PRE-BOOKING ACTIVITIES 
 Pre-booking activities consist of the following: 
  

	 	•	 	 discussions with potential customers to make them aware of the upcoming availability of the Generic Product as authorized generics from Watson, and

  

	 	•	 	 sales order booking (but not shipping) prior to the Launch Date. 

  

 B-1 

 EXHIBIT C 
 MAXIMUM MONTHLY WHOLE LOT QUANTITIES 
 [*] Whole Lots per month 
  

 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 

C-1 

 EXHIBIT D 
 PACKAGING CONFIGURATIONS 
 280 count bottles 
 500 count bottles 
  

 D-1 

 EXHIBIT E 
 EXAMPLE OF PROFIT SHARE CALCULATION 
 Net Sales for July 2007 are $110 and the Purchase Price paid by Watson for
Generic Product sold during July 2007 is $10. Profits are $100 (Net Sales less Purchase Price). Not later than September 15, 2007, Watson shall pay Salix $[*] ([*]% of Profits for July 2007). 
  

 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 
 E-1 

 EXHIBIT F 
 PROMOTIONAL ALLOWANCES 
  

	
	Invoice Price Correction Value
	Promotion Allowances Value
	Slotting Allowance Value
	Shelf Stock Adjustments Value

  

 F-1 

 EXHIBIT G 
 NET SALES AND PROFITS REPORTS 
  

								
		  	 	Profit Calculation	 	
	 Sample Figures Only
	  			 		 
		  	 	MTD	 		 
	 Gross invoice sales
	  	$	 	 	[*]	 
	  
 Cash discounts
	  	$	 	 	[*]	 
	 Chargebacks
	  	$	 	 	[*]	 
	 Rebate programs
	  	$	 	 	[*]	 
	 Returns
	  	$	 	 	[*]	 
	 Medicaid rebates
	  	$	 	 	[*]	 
	 Other - specific allocations
	  	$	 	 	[*]	 
	  
 Net Sales
	  	$	 	 	[*]	 
	  
 Material Costs
	  	$	 	 	[*]	 
	  
 Gross Profit
	  	$	 	 	[*]	 
	  
 Profit Due @
[*]%
	  	$	 	 	[*]	 

  

 [*] Confidential treatment requested; certain information omitted and filed separately with the SEC. 

G-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}]]